US20210017099A1 - Radiolabeling of polypeptides - Google Patents
Radiolabeling of polypeptides Download PDFInfo
- Publication number
- US20210017099A1 US20210017099A1 US16/955,094 US201816955094A US2021017099A1 US 20210017099 A1 US20210017099 A1 US 20210017099A1 US 201816955094 A US201816955094 A US 201816955094A US 2021017099 A1 US2021017099 A1 US 2021017099A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- binding fragment
- antigen binding
- click reaction
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 143
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 139
- 229920001184 polypeptide Polymers 0.000 title claims description 138
- 238000000163 radioactive labelling Methods 0.000 title abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 174
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000012650 click reaction Methods 0.000 claims description 119
- 230000027455 binding Effects 0.000 claims description 109
- 239000000427 antigen Substances 0.000 claims description 86
- 102000036639 antigens Human genes 0.000 claims description 86
- 108091007433 antigens Proteins 0.000 claims description 86
- 239000012634 fragment Substances 0.000 claims description 83
- 150000002500 ions Chemical class 0.000 claims description 76
- 150000001540 azides Chemical class 0.000 claims description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 239000013522 chelant Substances 0.000 claims description 51
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 35
- -1 213Bi Chemical compound 0.000 claims description 33
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 32
- 125000002355 alkine group Chemical group 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 25
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical group 0.000 claims description 24
- 150000001345 alkine derivatives Chemical class 0.000 claims description 22
- 238000002372 labelling Methods 0.000 claims description 21
- 235000000346 sugar Nutrition 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 125000002009 alkene group Chemical group 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 17
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 15
- 230000000269 nucleophilic effect Effects 0.000 claims description 15
- 230000001613 neoplastic effect Effects 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 150000001993 dienes Chemical class 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims description 10
- 108060008539 Transglutaminase Proteins 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000010348 incorporation Methods 0.000 claims description 9
- 102000003601 transglutaminase Human genes 0.000 claims description 9
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 8
- OYBOVXXFJYJYPC-UHFFFAOYSA-N 3-azidopropan-1-amine Chemical group NCCCN=[N+]=[N-] OYBOVXXFJYJYPC-UHFFFAOYSA-N 0.000 claims description 7
- 108060003306 Galactosyltransferase Proteins 0.000 claims description 7
- 102000030902 Galactosyltransferase Human genes 0.000 claims description 7
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 7
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 7
- 102000004357 Transferases Human genes 0.000 claims description 7
- 108090000992 Transferases Proteins 0.000 claims description 7
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 238000006206 glycosylation reaction Methods 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 108700023418 Amidases Proteins 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 102000005922 amidase Human genes 0.000 claims description 6
- 239000012039 electrophile Substances 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- 238000009966 trimming Methods 0.000 claims description 5
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 claims description 4
- ZMBGKXBIVYXREN-UHFFFAOYSA-N 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethanamine Chemical compound NCCOCCOCCOCCOCCN=[N+]=[N-] ZMBGKXBIVYXREN-UHFFFAOYSA-N 0.000 claims description 3
- CLQMAUAPICAWGT-UHFFFAOYSA-N 6-azidohexan-1-amine Chemical compound NCCCCCCN=[N+]=[N-] CLQMAUAPICAWGT-UHFFFAOYSA-N 0.000 claims description 3
- XOCCAGJZGBCJME-UHFFFAOYSA-N 6-deoxyGalNAc Natural products CC1OC(O)C(NC(C)=O)C(O)C1O XOCCAGJZGBCJME-UHFFFAOYSA-N 0.000 claims description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- 210000004027 cell Anatomy 0.000 description 82
- 238000006243 chemical reaction Methods 0.000 description 51
- 239000000203 mixture Substances 0.000 description 42
- 239000000872 buffer Substances 0.000 description 36
- 239000000243 solution Substances 0.000 description 29
- 241000282414 Homo sapiens Species 0.000 description 23
- 239000000562 conjugate Substances 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 229940125666 actinium-225 Drugs 0.000 description 18
- 239000010949 copper Substances 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 206010039073 rheumatoid arthritis Diseases 0.000 description 17
- 230000009920 chelation Effects 0.000 description 16
- 230000021615 conjugation Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 15
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000002738 chelating agent Substances 0.000 description 14
- 229940051022 radioimmunoconjugate Drugs 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 12
- 229960001972 panitumumab Drugs 0.000 description 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 11
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 11
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 11
- 229960005395 cetuximab Drugs 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 229960003330 pentetic acid Drugs 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 10
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
- 0 [1*]N1CCN([2*])CCN([3*])CCN([4*])C(C)C1 Chemical compound [1*]N1CCN([2*])CCN([3*])CCN([4*])C(C)C1 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000002285 radioactive effect Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 150000003536 tetrazoles Chemical class 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 8
- MGXFNZDANSIGCK-UHFFFAOYSA-N O=C(O)CN1CCN(CC(=O)O)CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C#CC4=C2C=CC=C4)C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 Chemical compound O=C(O)CN1CCN(CC(=O)O)CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C#CC4=C2C=CC=C4)C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 MGXFNZDANSIGCK-UHFFFAOYSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 229960000958 deferoxamine Drugs 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 229960002087 pertuzumab Drugs 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 102000004338 Transferrin Human genes 0.000 description 7
- 108090000901 Transferrin Proteins 0.000 description 7
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 7
- 150000001336 alkenes Chemical class 0.000 description 7
- 230000001143 conditioned effect Effects 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 239000012581 transferrin Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052767 actinium Inorganic materials 0.000 description 6
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229940049595 antibody-drug conjugate Drugs 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000611 antibody drug conjugate Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
- 102000046689 human FOLH1 Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- NHUQBUOYMWJTPB-UHFFFAOYSA-N 1,2-difluoro-5,6-didehydro-7,8,9,10-tetrahydrobenzo[8]annulene Chemical compound C1#CCCCCC2=C(F)C(F)=CC=C21 NHUQBUOYMWJTPB-UHFFFAOYSA-N 0.000 description 4
- ZJJAWGLRWHRNGC-UHFFFAOYSA-N 1,2-dimethoxy-1-azacyclooct-7-yne Chemical compound COC1CCCCC#CN1OC ZJJAWGLRWHRNGC-UHFFFAOYSA-N 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 4
- 101150029707 ERBB2 gene Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 description 4
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000012264 purified product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- BCWSMLLWYJYKHM-UHFFFAOYSA-N CC(=O)N(O)CCCCCCC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCCC(=O)CCC(=O)N1CC2=C(C#CC3=C1C=CC=C3)C=CC=C2 Chemical compound CC(=O)N(O)CCCCCCC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCCC(=O)CCC(=O)N1CC2=C(C#CC3=C1C=CC=C3)C=CC=C2 BCWSMLLWYJYKHM-UHFFFAOYSA-N 0.000 description 3
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 3
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 3
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 101710204410 Scaffold protein Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- OIGKWPIMJCPGGD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanoate Chemical compound [N-]=[N+]=NCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O OIGKWPIMJCPGGD-UHFFFAOYSA-N 0.000 description 2
- GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 description 2
- DSNRETVSVKDBRT-UHFFFAOYSA-N 2-[6-[[4-[[3-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-3-oxopropyl]carbamothioylamino]phenyl]methyl]-4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)C(Cc2ccc(NC(=S)NCCC(=O)N3Cc4ccccc4C#Cc4ccccc34)cc2)CN(CC(O)=O)CC1 DSNRETVSVKDBRT-UHFFFAOYSA-N 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 2
- AQWXHYUWFUXFFH-UHFFFAOYSA-N 3-[4,7,10-tris(2-carboxyethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCN(CCC(O)=O)CCN(CCC(O)=O)CCN(CCC(O)=O)CC1 AQWXHYUWFUXFFH-UHFFFAOYSA-N 0.000 description 2
- SOUJYUTZZAWCOV-UHFFFAOYSA-N 3-[4,8,11-tris(2-carboxyethyl)-1,4,8,11-tetrazacyclotetradec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCCN(CCC(O)=O)CCN(CCC(O)=O)CCCN(CCC(O)=O)CC1 SOUJYUTZZAWCOV-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 101710130081 Aspergillopepsin-1 Proteins 0.000 description 2
- BDVUMZPEKZGSFW-UHFFFAOYSA-N C.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCCC(=O)CCC(=O)N1CC2=C(C#CC3=C1C=CC=C3)C=CC=C2 Chemical compound C.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCCC(=O)CCC(=O)N1CC2=C(C#CC3=C1C=CC=C3)C=CC=C2 BDVUMZPEKZGSFW-UHFFFAOYSA-N 0.000 description 2
- FQIQILFKORVTBB-ZQSXMSGHSA-N C/C1=O/[89Zr]2345ON(CCCCCNC(=O)CC/C(=O\2)N(CCCCCCC(=O)CCC(=O)N2CC6=C(C=CC=C6)C6=C(N=NN6C)C6=C2C=CC=C6)O3)C(=O4)CCC(=O)NCCCCCN1O5 Chemical compound C/C1=O/[89Zr]2345ON(CCCCCNC(=O)CC/C(=O\2)N(CCCCCCC(=O)CCC(=O)N2CC6=C(C=CC=C6)C6=C(N=NN6C)C6=C2C=CC=C6)O3)C(=O4)CCC(=O)NCCCCCN1O5 FQIQILFKORVTBB-ZQSXMSGHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 2
- 238000005698 Diels-Alder reaction Methods 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 102100028875 Formylglycine-generating enzyme Human genes 0.000 description 2
- 101710192607 Formylglycine-generating enzyme Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- PSCMQHVBLHHWTO-UHFFFAOYSA-K Indium trichloride Inorganic materials Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- MJWSCMQHZYLXCB-BITMAZLMSA-N O=C=O.O=C=O.[225Ac].[H]CN1CCN(C[H])CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C=CC=C3)C3=C(N=NN3C)C3=C2C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 Chemical compound O=C=O.O=C=O.[225Ac].[H]CN1CCN(C[H])CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C=CC=C3)C3=C(N=NN3C)C3=C2C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 MJWSCMQHZYLXCB-BITMAZLMSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 229910052776 Thorium Inorganic materials 0.000 description 2
- 229910007932 ZrCl4 Inorganic materials 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- OCCYFTDHSHTFER-UHFFFAOYSA-N dbco-amine Chemical compound NCCC(=O)N1CC2=CC=CC=C2C#CC2=CC=CC=C12 OCCYFTDHSHTFER-UHFFFAOYSA-N 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940055742 indium-111 Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052755 nonmetal Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000011363 radioimmunotherapy Methods 0.000 description 2
- 229910052705 radium Inorganic materials 0.000 description 2
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MRYQZMHVZZSQRT-UHFFFAOYSA-M tetramethylazanium;acetate Chemical compound CC([O-])=O.C[N+](C)(C)C MRYQZMHVZZSQRT-UHFFFAOYSA-M 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BYBCIVKIWIFVFD-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-(2,6-dioxooxan-3-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN1C1C(=O)OC(=O)CC1 BYBCIVKIWIFVFD-UHFFFAOYSA-N 0.000 description 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 1
- MXDPZUIOZWKRAA-PRDSJKGBSA-K 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(1s,2r)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-y Chemical compound [177Lu+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1)C1=CC=CC=C1 MXDPZUIOZWKRAA-PRDSJKGBSA-K 0.000 description 1
- RARDFYXVWPZNTG-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid methanol hydrate Chemical compound O.OC.OC(=O)CC(O)(C(O)=O)CC(O)=O RARDFYXVWPZNTG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- LFESCIZZXSUBAV-UHFFFAOYSA-N CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N1CC2=C(C#CC3=C1C=CC=C3)C=CC=C2 Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N1CC2=C(C#CC3=C1C=CC=C3)C=CC=C2 LFESCIZZXSUBAV-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000711455 Homo sapiens Kinetochore protein Spc25 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZFWRJAPRJVJBQO-UCFBMCHYSA-N O=C=O.O=C=O.[111InH3].[H]CN1CCN(C[H])CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C=CC=C3)C3=C(N=NN3C)C3=C2C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 Chemical compound O=C=O.O=C=O.[111InH3].[H]CN1CCN(C[H])CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C=CC=C3)C3=C(N=NN3C)C3=C2C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 ZFWRJAPRJVJBQO-UCFBMCHYSA-N 0.000 description 1
- UTCVTCQOBNYXLJ-BITMAZLMSA-N O=C=O.O=C=O.[89Zr].[H]CN1CCN(C[H])CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C=CC=C3)C3=C(N=NN3C)C3=C2C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 Chemical compound O=C=O.O=C=O.[89Zr].[H]CN1CCN(C[H])CCN(C(CCC(=O)NCCC(=O)N2CC3=C(C=CC=C3)C3=C(N=NN3C)C3=C2C=CC=C3)C(=O)O)CCN(CC(=O)O)CC1 UTCVTCQOBNYXLJ-BITMAZLMSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101710192761 Serine-type anaerobic sulfatase-maturating enzyme Proteins 0.000 description 1
- 102100023776 Signal peptidase complex subunit 2 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920006322 acrylamide copolymer Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-aminopropionic acid Natural products NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 108010045676 holotransferrin Proteins 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 150000007855 nitrilimines Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 238000002727 particle therapy Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 108090000250 sortase A Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 150000004905 tetrazines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- QCWXUUIWCKQGHC-YPZZEJLDSA-N zirconium-89 Chemical compound [89Zr] QCWXUUIWCKQGHC-YPZZEJLDSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Definitions
- This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name “Sequence_Listing”, creation date of Dec. 7, 2018, and having a size of about 13.2 kB.
- sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.
- the invention relates to methods for radiolabeling polypeptides, such as antibodies.
- the invention relates to methods of using click chemistry to label a polypeptide with a radiometal ion.
- the invention also relates to pharmaceutical compositions and uses of the radiolabeled polypeptides.
- Alpha particle-emitting radionuclides have great promise for cancer therapy due to their combination of high energy with short-range action, providing the possibility of potent killing that is mostly localized to tumor cells (Kim, Y. S. and M. W. Brechbiel, An overview of targeted alpha therapy. Tumour Biol, 2012. 33(3): p. 573-90).
- Targeted delivery of alpha-emitters, using an antibody, scaffold protein, small molecule ligand, aptamer, or other binding moiety that is specific for a cancer antigen provides a method of selective delivery of the radionuclide to tumors to enhance their potency and mitigate off-target effects.
- the binding moiety is attached to a chelator which binds to the alpha-emitting radiometal to produce a radiocomplex.
- a chelator which binds to the alpha-emitting radiometal to produce a radiocomplex.
- Many such examples use a monoclonal antibody (mAb) as the targeting ligand, to produce what is known as a radioimmunoconjugate.
- mAb monoclonal antibody
- Actinium-225 ( 225 Ac) is an alpha-emitting radioisotope that is of particular interest for medical applications (Miederer et al., Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev, 2008. 60(12):71-82).
- the 10-day half-life of 225 Ac is long enough to facilitate radio-conjugate production, but short enough to match the circulation pharmacokinetics of delivery vehicles such as antibodies.
- 225 Ac radioimmunoconjugates are of particular interest.
- 225 Ac decays in a series of steps that ultimately emits 4 alpha particles before reaching a stable isotope, 209 Bi, thereby increasing the potency.
- 177 Lu Lutetium-177
- 177 Lu-labeled peptides demonstrate reduced normal tissue damage
- 177 Lu-labeling makes it possible to use a single radiolabeled agent for both therapy and imaging (Kwekkeboom D J, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28: p. 1319-1325).
- radioisotopes that are used for therapeutic applications include, e.g., beta or alpha emitters, such as, e.g., thorium, radium, 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 255 Fm and 227 Th.
- beta or alpha emitters such as, e.g., thorium, radium, 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er,
- radioisotopes that are used for imaging applications include gamma-emitting radioisotopes, such as, e.g., 62 Cu, 64 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, and 111 In.
- the “2-step” method which includes 2 chemical steps involving actinium, was the first to be developed (McDevitt, M. R., et al., Tumor therapy with targeted atomic nanogenerators. Science, 2001. 294(5546): p. 1537-40).
- 225 Ac was chelated by the bifunctional chelator (BFC) DOTA-isothiocyanate (DOTA-SCN) in high radiochemical yield ( ⁇ 95%) at pH 4.5-5 using 2 M acetate buffer at 55° to 60° C. for 30 min. Subsequently, the 225 Ac-DOTA-SCN was reacted with the targeting antibody to produce the radioimmunoconjugate.
- BFC bifunctional chelator
- DOTA-isothiocyanate DOTA-isothiocyanate
- the major drawback of the 2-step method is that ⁇ 90% of the SCN fails to survive the labeling conditions, thus ⁇ 90% of the input 225 Ac is conjugated to nonreactive forms of DOTA that cannot be conjugated to the antibody. This results in not only low yield (typically only about 10%) and higher costs, but also lowered specific activity that can limit the efficacy of the final conjugate.
- the “1-step” method was developed more recently for actinium (Maguire, W. F., et al., Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for alpha-particle radioimmunotherapy of cancer. J Nucl Med, 2014. 55(9): p. 1492-8). This method has only 1 chemical reaction step involving actinium.
- the DOTA-SCN was first conjugated to the antibody.
- the 225 Ac was then chelated to the DOTA-mAb under mild conditions (37° C., pH 7.5), achieving up to 80% radiochemical yield.
- the high chelator:antibody ratio (CAR), in this case the high DOTA:Ab ratio (DAR), species are more likely to have compromised immunoreactivity; furthermore, though the average DAR may be 10, it is likely that the 225 Ac is chelating to populations with ratios even higher than the average.
- this method runs the risk of linking the 225 Ac to the least active fraction of antibody-chelator conjugates.
- it is necessary to handle the antibody and DOTA-mAb conjugate under metal-free conditions to avoid chelation of common metals such as iron, zinc and copper, which introduces significant challenges into the production process.
- Click chemistry is a chemical approach introduced by Sharpless in 2001 and describes chemistry tailored to generate substances quickly and reliably by joining small units together. See, e.g., Kolb, Finn and Sharpless Angewandte Chemie International Edition (2001) 40: 2004-2021; Evans, Australian Journal of Chemistry (2007) 60: 384-395).
- Coupling reactions include, but are not limited to, formation of esters, thioesters, amides (e.g., such as peptide coupling) from activated acids or acyl halides; nucleophilic displacement reactions (e.g., such as nucleophilic displacement of a halide or ring opening of strained ring systems); azide-alkyne Huisgen cycloaddition (e.g., 1,3-dipolar cycloaddition between an azide and an alkyne to form a 1,2,3-triazole linker); thiolyne addition; imine formation; Diels-Alder reactions between tetrazines and trans-cyclooctene (TCO); and Michael additions (e.g., maleimide addition).
- nucleophilic displacement reactions e.g., such as nucleophilic displacement of a halide or ring opening of strained ring systems
- Click chemistry reactions between alkynes and azides typically require the addition of a copper catalyst to promote the 1,3-cycloaddition reaction, and are known as copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions.
- CuAAC copper-catalyzed azide-alkyne cycloaddition
- click chemistry reactions between cyclooctyne or cyclooctyne derivatives and azides typically do not require the addition of a copper catalyst, and instead proceed via strain-promoted azide-alkyne cycloaddition (SPAAC) (Debets, M. F., et al., Bioconjugation with strained alkenes and alkynes. Acc Chem Res, 2011. 44(9): p. 805-15).
- SPAAC strain-promoted azide-alkyne cycloaddition
- ADC antibody-drug conjugate
- the invention satisfies this need by providing methods for using click chemistry to radiolabel polypeptides, such as antibodies.
- an azide-modified antibody and a radiocomplex comprising a radiometal ion associated with a chelating moiety comprising an alkyne group are used in a click chemistry reaction to produce stable radioimmunoconjugates having a low chelator:antibody ratio (CAR) and high radiochemical yields, while requiring reduced usage of the radioactive metal and only requiring metal-free conditions in the step used to produce the initial radiocomplex.
- CAR chelator:antibody ratio
- Methods of the invention simplify previous methods for producing radioimmunoconjugates with increased safety, efficacy and uniformity.
- the invention relates to a method of labeling a polypeptide with a radiometal ion, the method comprising:
- the invention in another general aspect, relates to a pharmaceutical composition
- a pharmaceutical composition comprising a radiolabeled polypeptide prepared by a method of the invention and a pharmaceutically acceptable carrier.
- the invention in another general aspect, relates to a method of treating a neoplastic disease or disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the invention.
- the invention relates to a combination or kit comprising:
- the invention relates to a therapeutic or diagnostic agent (“theranostic agent”) comprising a radiolabeled polypeptide prepared by a method of the invention.
- FIG. 1 shows a schematic of radiolabeling an antibody according to a method of the invention; random conjugation is shown in the figure, and a similar radiolabeling scheme is used when the azides are conjugated to the monoclonal antibody (mAb) site-specifically;
- mAb monoclonal antibody
- FIG. 2 shows a synthesis scheme of an improved two-step preparation of 89 Zr-DOTA-mAb via click chemistry according to an embodiment of the application
- FIG. 3 shows cell binding of In-111 radioimmunoconjugates: bound radioactivity increases with increasing cell number; in particular:
- FIG. 3A shows the binding to the human prostate cancer cell line C4-2B (PSMA+, Transferrin receptor+) by a PSMA-binding antibody (“PSMB127”) In-111 radioimmunoconjugate and a human transferrin In-111 radioconjugate according to embodiments of the application; and
- PSMB127 PSMA-binding antibody
- FIG. 3B shows the binding to the human epidermoid carcinoma cancer cell line A431 (EGFR+) by EGFR-binding antibodies cetuximab and panitumumab In-111 radioimmunoconjugates according to embodiments of the application, and the lack of binding of these conjugates to the control (EGFR ⁇ ) human AML cell line MOLM-13;
- FIG. 4 shows kinetics of cell internalization of In-111 in the human prostate cancer cell line C4-2B treated with a anti-PSMA mAb In-111 radioimmunoconjugate according to an embodiment of the application; surface-bound In-111 rapidly disappeared from the cell surface and was redistributed intracellularly; and
- FIG. 5 shows the results of a mouse tumor xenograft study; mice were implanted with human prostate cancer LNCaP cells; when tumors reached 100 mm 3 , mice were treated with a single dose of a click radiolabeled anti-PSMA mAb (“PSMB127”) actinium radioconjugate according to an embodiment of the application at a range of activities or the isotype control, a human IgG4 antibody that binds to a viral target absent in this system radioconjugate; in particular:
- PSMB127 click radiolabeled anti-PSMA mAb
- FIG. 5A shows the tumor volume for each group; sizes were plotted until under half of the group remained;
- FIG. 5B shows survival curves for control mAb groups
- FIG. 5C shows survival curves for anti-PSMA mAb groups.
- the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or”, a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or.”
- methods of the present invention provide for an improved method for the production of radioimmunoconjugates that are suitable, for example, for medicinal applications in subjects, e.g., humans, in need thereof.
- methods described herein address the major limitations of current methods by providing processes for both high yield chelation of metal ions, including but not limited to, 225 Ac, 111 In and 89 Zr, and for low DAR.
- the invention allows for the production of a single batch of azide-labeled polypeptides, such as azide-mAb conjugate that can then be used for the production of a radiolabeled diagnostic (e.g., when labeled with 89 Zr or 111 In) or therapeutic (e.g., when labeled with 225 Ac) purposes, in which the radiolabel is attached at the same site(s) within the batch of azide-labeled polypeptides, which can be obtained either by site-specific modification or by random azide conjugation.
- a radiolabeled diagnostic e.g., when labeled with 89 Zr or 111 In
- therapeutic e.g., when labeled with 225 Ac
- samples of a batch of azide-labeled polypeptides comprising a single distribution of azide-modified sites can be radiolabeled for different purposes using click chemistry of the invention.
- a method of the invention which relies on click chemistry and is referred to as “click radiolabeling”, involves (1) obtaining a modified polypeptide, such as an antibody, that includes a first click chemistry reaction partner, e.g. an azide moiety; (2) obtaining a radiocomplex comprising a radiometal ion, e.g., 225 Ac, 111 In or 89 Zr, associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently liked to a second click chemistry reaction partner, e.g.
- an alkyne group such as DOTA-dibenzocyclooctyne (DOTA-DBCO) or deferoxamine-DBCO (DFO-DBCO); and (3) conducting a reaction between the click chemistry reaction partners of the modified peptide and the radiocomplex, such as a strain-promoted alkyne-azide cycloaddition (SPAAC) between the azide moiety and the alkyne group.
- DOTA-dibenzocyclooctyne DOTA-dibenzocycloctyne
- DFO-DBCO deferoxamine-DBCO
- a method of the invention allows chelation of the radioactive metal under low or high pH and/or high temperature conditions to maximize efficiency, which can be accomplished without the risk of inactivating the alkyne reaction partner.
- the efficient chelation and efficient SPAAC reaction between azido-mAb and the radiocomplex allows radioimmunoconjugates to be produced with high radiochemical yield even with low azide:mAb ratios.
- the only step in which trace metals must be excluded is the radiometal ion chelation to the chelating moiety; the antibody production, purification, and conjugation steps do not need to be conducted under metal free conditions.
- click chemistry refers to a chemical philosophy introduced by Sharpless, describing chemistry tailored to generate covalent bonds quickly and reliably by joining small units comprising reactive groups together (see Kolb, et al., supra). Click chemistry does not refer to a specific reaction, but to a concept including, but not limited to, reactions that mimic reactions found in nature. In some embodiments, click chemistry reactions are modular, wide in scope, give high chemical yields, generate inoffensive byproducts, are stereospecific, exhibit a large thermodynamic driving force to favor a reaction with a single reaction product, and/or can be carried out under physiological conditions.
- a click chemistry reaction exhibits high atom economy, can be carried out under simple reaction conditions, uses readily available starting materials and reagents, uses no toxic solvents or uses a solvent that is benign or easily removed, such as water, and/or provides simple product isolation by non-chromatographic methods, such as crystallization or distillation.
- the click chemistry reaction is a Huisgen cycloaddition or the 1,3-dipolar cycloaddition between an azide (—N3) and an alkyne, or an alkyne moiety, to form a 1,2,4-triazole linker.
- the invention relates to a method of labeling a polypeptide, an aptamer, or a small molecule ligand with a radiometal ion, the method comprising:
- polypeptide refers to a polymer composed of amino acid residues, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof linked via peptide bonds.
- the term refers to a polypeptide of any size, structure, or function. Typically, a polypeptide is at least three amino acids long.
- a polypeptide can be naturally occurring, recombinant, or synthetic, or any combination thereof. Synthetic polypeptides can be synthesized, for example, using an automated polypeptide synthesizer.
- the polypeptide is an antibody, preferably a monoclonal antibody, or a fragment thereof, such as an antigen-binding fragment thereof.
- the antibody or fragment thereof is specific for a cancer antigen.
- the polypeptide is an engineered domain or a scaffold protein.
- antibody or “immunoglobulin” is used in a broad sense and includes immunoglobulin or antibody molecules including polyclonal antibodies, monoclonal antibodies including murine, human, human-adapted, humanized and chimeric monoclonal antibodies, and antigen-binding fragments thereof.
- antibodies are proteins or peptide chains that exhibit binding specificity to a specific antigen, referred to herein as a “target”.
- Antibody structures are well known.
- Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence.
- IgA and IgG are further sub-classified as the isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4.
- the antibodies of the invention can be of any of the five major classes or corresponding sub-classes.
- the antibodies of the invention are IgG1, IgG2, IgG3 or IgG4.
- Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains. Accordingly, the antibodies of the invention can contain a kappa or lambda light chain constant domain. According to particular embodiments, the antibodies of the invention include heavy and/or light chain constant regions from mouse antibodies or human antibodies. Each of the four IgG subclasses has different biological functions known as effector functions. These effector functions are generally mediated through interaction with the Fc receptor (Fc ⁇ R) or by binding C1q and fixing complement. Binding to Fc ⁇ R can lead to antibody dependent cell mediated cytolysis, whereas binding to complement factors can lead to complement mediated cell lysis. An antibody useful for the invention can have no or minimal effector function, but retain its ability to bind FcRn.
- Fc ⁇ R Fc receptor
- An antibody useful for the invention can have no or minimal effector function, but retain its ability to bind FcRn.
- the term “antigen-binding fragment” refers to an antibody fragment such as, for example, a diabody, a Fab, a Fab′, a F(ab′)2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv′), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), a single domain antibody (sdab) an scFv dimer (bivalent diabody), a multispecific antibody formed from a portion of an antibody comprising one or more CDRs, a camelized single domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not comprise a complete antibody structure.
- an antibody fragment such as, for example, a diabody, a Fab, a
- an antigen-binding fragment is capable of binding to the same antigen to which the parent antibody or a parent antibody fragment binds.
- the term “single-chain antibody” refers to a conventional single-chain antibody in the field, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to about 20 amino acids.
- the term “single domain antibody” refers to a conventional single domain antibody in the field, which comprises a heavy chain variable region and a heavy chain constant region or which comprises only a heavy chain variable region.
- scaffold refers to any protein that has a target binding domain and that can bind to a target.
- a scaffold contains a “framework”, which is largely structural, and a “binding domain” which makes contact with the target and provides for specific binding.
- the binding domain of a scaffold need not be defined by one contiguous sequence of the scaffold.
- a scaffold may be part of larger binding protein, which, itself, may be part of a multimeric binding protein that contains multiple scaffolds.
- Certain binding proteins may be bi- or multi-specific in that they can bind to two or more different epitopes.
- a scaffold can be derived from a single chain antibody, or a scaffold may be not antibody-derived.
- Polypeptides of the invention can be covalently linked to a first click reaction partner using any method for chemical or enzymatic modification of a polypeptide known to those skilled in the art in view of the present disclosure.
- Amine-reactive groups that react with primary amines that exist at the N-terminus of each polypeptide chain and in the side-chain of lysine residues can be used in methods for random modification of polypeptides.
- Examples of amine-reactive groups suitable for use in the invention include, but are not limited to, N-hydroxy succinimide (NHS), substituted NHS, such as sulfo-NHS, isothiocyanate, and tetra- and per-fluoro phenyl ester.
- Thiol-reactive groups that react with thiols, or sulfhydryls, that exist in the side-chain of cysteine residues can be used in methods for random modification of polypeptides.
- thiol-reactive groups suitable for use in the invention include, but are not limited to, maleimide, haloacetyl and phenyloxadiazole sulfone.
- a modified polypeptide is obtained by reacting a side chain, preferably the amino side chain of a lysine, with an electrophile covalently linked to the first click reaction partner (e.g. NHS-azide).
- a method of the invention further allows the production of site-specific radiolabeled polypeptides.
- the click radiolabeling method of the invention facilitates site-specific production of radioimmunoconjugates by taking advantage of established methods to install azide groups site-specifically on antibodies (Li, X., et al. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl, 2014. 53(28): p. 7179-82; Xiao, H., et al., Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew Chem Int Ed Engl, 2013.
- Examples of methods to site-specifically modify antibodies suitable for use in the invention include, but are not limited to, incorporation of engineered cysteine residues (e.g., THIOMABTM), use of non-natural amino acids or glycans (e.g., seleno cysteine, p-AcPhe, formylglycine generating enzyme (FGE, SMARTagTM), etc.), and enzymatic methods (e.g., use of glycotransferase, endoglycosidase, microbial or bacterial transglutaminase (MTG or BTG), sortase A, etc.).
- engineered cysteine residues e.g., THIOMABTM
- non-natural amino acids or glycans e.g., seleno cysteine, p-AcPhe, formylglycine generating enzyme (FGE, SMARTagTM), etc.
- enzymatic methods e.g., use of glycotrans
- the modified polypeptide is an antibody or antigen binding fragment thereof that is obtained by trimming the antibody or antigen binding fragment thereof with a bacterial endoglycosidase specific for the ⁇ -1,4 linkage between a core GlcNac residue in a Fc-glycosylation site of the antibody, such as GlycINATOR (Genovis), which leaves the inner most GlcNAc intact on the Fc, allowing for the site-specific incorporation of azido sugars at that site.
- GlycINATOR Geneovis
- modified polypeptide is an antibody or antigen binding fragment thereof that is obtained by deglycosylating the antibody or antigen binding fragment thereof with an amidase.
- the resulting deglycosylated antibody or antigen binding fragment thereof can then be reacted with an azido amine, preferably 3-azido propylamine, 6-azido hexylamine, or any azido-linker-amine or any azido-alkyl-amine, such as an azido-polyethylene glycol (PEG)-amine, for example, 0-(2-Aminoethyl)-O′-(2-azidoethyl)tetraethylene glycol, 0-(2-Aminoethyl)-O′-(2-azidoethyl)pentaethylene glycol, O-(2-Aminoethyl)-O′-(2-azidoethyl)triethylene glycol, etc., or in the presence of a microbial transglutaminase to thereby obtain the modified antibody or antigen binding fragment thereof.
- an azido amine preferably 3-azido propylamine, 6-a
- aptamer refers to a single-stranded oligonucleotide (single-stranded DNA or RNA molecule) that can bind specifically to its target with high affinity.
- the aptamer can be used as a molecule targeting various organic and inorganic materials.
- small molecule ligand refers to a low molecular weight organic compound. Small molecule ligands, as used herein, can refer to compounds that have a size of less than about 1000 daltons, and can be synthesized in the laboratory or found in nature.
- click reaction partner or “click chemistry handle” refers to a reactant or a reactive group that can partake in a click chemistry reaction.
- a click reaction partner can be a moiety that is rarely found in naturally-occurring biomolecules and is chemically inert towards biomolecules, but, e.g., when reacted with an azide-reactive or alkyne-reactive group, the reaction can take place efficiently under biologically relevant conditions, for example in cell culture conditions, such as in the absence of excess heat or harsh reactants.
- click chemistry reactions require at least two molecules comprising click reaction partners that can react with each other.
- click reaction partners that are reactive with each other are sometimes referred to herein as click chemistry handle pairs, or click chemistry pairs.
- the click reaction partners are an azide and a strained alkyne, e.g. a cyclooctyne, or any other alkyne.
- the click reaction partners are reactive dienes and suitable tetrazine dienophiles. For example, trans-cyclooctene, norbornene, or biscyclononene can be paired with a suitable tetrazine dienophile as a click reaction pair.
- tetrazoles can act as latent sources of nitrile imines, which can pair with unactivated alkenes in the presence of ultraviolet light to create a click reaction pair, termed a “photo-click” reaction pair.
- the click reaction partners are a cysteine and a maleimide.
- the cysteine from a peptide e.g., GGGC
- a maleimide that is associated with a chelating agent (e.g., NOTA).
- chelating agent e.g., NOTA
- Other suitable click chemistry handles are known to those of skill in the art (see, e.g., Spicer et al., Selective chemical protein modification. Nature Communications. 2014; 5: p. 4740).
- the click reaction partners are Staudinger ligation components, such as phosphine and azide.
- the click reaction partners are Diels-Alder reaction components, such as dienes, such as tetrazine, and alkenes, such as trans-cyclooctene (TCO) or norbornene.
- TCO trans-cyclooctene
- Exemplary click reaction partners are described in US20130266512 and in WO2015073746, the relevant description on click reaction partners in both of which are incorporated by reference herein.
- one of the first and second click reaction partners comprises an alkyne group, and the other click reaction partner comprises an azide.
- one of the first and second click reaction partners comprises an alkene group, and the other click reaction partner comprises a diene.
- alkyne refers to a functional group comprising a carbon-carbon triple bond.
- Alkyne moieties include terminal alkynes and cyclic alkynes, preferably terminal alkynes and cyclic alkynes that are reactive with azide groups.
- a terminal alkyne has at least one hydrogen atom bonded to a triply bonded carbon atom.
- a cyclic alkyne is a cycloalkyl ring comprising one or more triple bonds.
- cyclic alkynes include, but are not limited to, cyclooctyne and cyclooctyne derivatives, such as bicyclononyne (BCN), difluorinated cyclooctyne (DIFO), dibenzocyclooctyne (DIBO), keto-DIBO, biarylazacyclooctynone (BARAC), dibenzoazacyclooctyne (DIBAC), dimethoxyazacyclooctyne (DIMAC), dibenzyocyclooctyne (DBCO), difluorobenzocyclooctyne (DIFBO), monobenzocyclooctyne (MOBO), and tetramethoxy DIBO (TMDIBO).
- BCN bicyclononyne
- DIFO difluorinated cyclooctyne
- DIBO dibenzocyclooctyne
- diene refers to a compound having two carbon-to-carbon double bonds where these double bonds are conjugated in the 1,3-position.
- the double bonds of the diene can be either cis or trans.
- dienes include, but are not limited to, a tetrazine or a tetrazole group.
- alkene refers to an unsaturated hydrocarbon molecule that includes a carbon-carbon double bond.
- an alkene can include from 2 to 100 carbon atoms.
- alkenes include, but are not limited to, norbornene and trans-cyclooctene (TCO).
- one of the first and second click reaction partners comprises an alkene group, preferably norbornene or TCO.
- the other click reaction partner comprises a diene, preferably a tetrazine or tetrazole group.
- covalently linked means that the polypeptide is attached to the first click reaction partner via at least one covalent linkage, and that the chelant is attached to the second click reaction partner via at least one covalent linkage.
- the linkage can be direct, i.e. without a linker, or indirect, i.e. via a linker.
- linker refers to a chemical moiety that joins a polypeptide or a chelant to a click reaction partner. Any suitable linker known to those skilled in the art in view of the present disclosure can be used in the invention.
- the linkers can be, for example, a single covalent bond, a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl moiety, a polyethylene glycol (PEG) linker, a peptide linker, a sugar-based linker, or a cleavable linker, such as a disulfide linkage or a protease cleavage site such as valine-citrulline-PAB.
- PEG polyethylene glycol
- radioactive metal ion refers to one or more isotopes of the elements that emit particles and/or photons. Any radioactive metal known to those skilled in the art in view of the present disclosure can be used in the invention.
- radioactive metals suitable for use in the invention include, but are not limited to, 32 P, 47 Sc, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 77 As, 86 Y, 89 Zr, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 111 In, 117 Sn, 131 I, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, and 255 Fm.
- diagnostic emitter refers to a radiometal ion that is useful in diagnostic or imaging applications.
- diagnostic emitters include, but are not limited to gamma emitters, such as 62 Cu, 64 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, and 111 In.
- therapeutic emitter refers to a radiometal ion that is useful in therapeutic applications.
- therapeutic emitters include, but are not limited to, beta or alpha emitters, such as thorium, radium, 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 255 Fm and 227 Th.
- the radiometal ion is 225 Ac.
- the polypeptide can be labeled with non-metal radiolabels for use in pre-targeting or theranostic applications.
- non-metal radiolabels suitable for use in the invention include, but are not limited to, 125 and 18 F.
- Radiocomplexes described herein comprise a radiometal ion associated with a chelating moiety.
- the chelating moiety comprises a chelant covalently linked to a click reaction partner, and is sometimes referred to herein as a “bifunctional chelator.”
- the term “chelant” or “chelator” refers to a chemical compound to which a radiometal, such as 225 Ac, or metal can be chelated via coordinate bonding. Any chelant known to those skilled in the art in view of the present disclosure can be used in the invention.
- the chelant comprises a macrocycle. Examples of chelants comprising a macrocycle suitable for use in the invention include, but are not limited to, deferoxamine (DFO), ethylenediaminetetraacetic acid (EDTA), and diethylenetriaminepentaacetic acid (DTPA).
- DFO deferoxamine
- EDTA ethylenediaminetetraacetic acid
- DTPA diethylenetriaminepentaacetic acid
- the chelant comprises an open chain ligand.
- chelants comprising an open chain ligand suitable for use in the invention include, but are not limited to, 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N′′,N′′′,N′′′′,N′′′′′-hexaacetic acid (HEHA), 1,4,7,10,13-pentaazacyclopentanadecane-N,N′,N′′,N′′′, N′′′′-pentaacetic acid (PEPA), Macropa (Thiele et al., An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.
- DOTA 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid
- HEHA 1,4,7
- the chelant comprises a structure of formula (I):
- each of R 1 , R 2 , R 3 and R 4 is independently CHQCO 2 X, wherein
- Q is independently hydrogen, C 1 -C 4 alkyl or (C 1 -C 2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C 1 -C 4 alkyl
- Z is (CH 2 ) n Y, wherein
- n 1-10
- Y is an electrophilic or nucleophilic moiety covalently linked to the second click reaction partner
- Z is hydrogen
- each of R 1 , R 2 , R 3 and R 4 is independently CHQCO 2 X, wherein
- Q is independently hydrogen, C 1 -C 4 alkyl or (C 1 -C 2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C 1 -C 4 alkyl, or an electrophilic or nucleophilic moiety covalently linked to the second click reaction partner.
- the chelating moiety comprises the structure of formula (II):
- the chelating moiety comprises the structure of formula (III):
- the invention relates to a method of labeling a polypeptide with two or more radiometal ions using a method of the invention.
- a method of dually labeling a polypeptide with two radiometal ions comprises:
- one of the first and second click reaction partners comprises an alkyne group, and the other of the first and second click reaction partner comprises an azide, and wherein one of the third and fourth click reaction partners comprises an alkene group, and the other of the third and fourth click reaction partner comprises a diene.
- the first or second radiometal ion is a diagnostic emitter, and the other is a therapeutic emitter. According to other preferred embodiments, both the first and second radiometal ions are therapeutic emitters.
- Conditions for carrying out click chemistry reactions are known in the art, and any conditions for carrying out click chemistry reactions known to those skilled in the art in view of the present disclosure can be used in the invention.
- Examples of conditions include, but are not limited to, incubating the modified polypeptide and the radiocomplex at a ratio of 1:1 to 1000:1 at a pH of 4 to 10 and a temperature of 20° C. to 70° C.
- Products of click radiolabeling methods of the invention can be analyzed using methods known to those skilled in the art in view of the present disclosure.
- LC/MS analysis can be used to determine the ratio of the chelator to the labeled polypeptide
- analytical size-exclusion chromatography can be used to determine the oligomeric state of the polypeptides and polypeptide conjugates
- radiochemical yield can be determined by instant thin layer chromatography (e.g. iTLC-SG), and radiochemical purity can be determined by size-exclusion HPLC. Exemplary methods are described herein, e.g., in the Examples below.
- the click radiolabeling method of the invention can be modified into a pre-targeting approach (Kraeber-Bodere, F., et al., A pretargeting system for tumor PET imaging and radioimmunotherapy. Front Pharmacol, 2015. 6: p. 54).
- the azido-mAb is dosed, binds to target cells, and is allowed to clear from circulation over time or removed with a clearing agent.
- the radiocomplex is administered and undergoes the SPAAC reaction with azido-mAbs bound at the target site, while the remaining unbound radiocomplex clears rapidly from circulation (Deal, K. A., et al., Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem, 1999. 42(15): p. 2988-92).
- This pre-targeting technique provides a method of enhancing radiometal ion localization at a target site in a subject
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a radiolabeled polypeptide prepared by a method of the invention and a pharmaceutically acceptable carrier.
- the term “carrier” refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid containing vesicle, microsphere, liposomal encapsulation, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient or diluent will depend on the route of administration for a particular application.
- the term “pharmaceutically acceptable carrier” refers to a non-toxic material that does not interfere with the effectiveness of a composition according to the invention or the biological activity of a composition according to the invention. According to particular embodiments, in view of the present disclosure, any pharmaceutically acceptable carrier suitable for use in an antibody-based, or a radiocomplex-based pharmaceutical composition can be used in the invention.
- compositions described herein are formulated to be suitable for the intended route of administration to a subject.
- the compositions described herein can be formulated to be suitable for intravenous, subcutaneous, intramuscular or intratumoral administration.
- the modified polypeptide and the radiocomplex can be administered in the same or different compositions.
- the invention in another general aspect, relates to a method of treating a neoplastic disease or disorder in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of the invention.
- a method of the invention comprises administering a therapeutically effective dose of a pharmaceutical composition of the invention, wherein the composition comprises a radiolabeled polypeptide for targeting cells associated with the neoplastic disease or disorder such that, upon targeting, alpha particles from the 5 Ac and daughters thereof are delivered to the targeted cells and cause a cytotoxic effect thereto, thereby treating the neoplastic disease or disorder.
- therapeutically effective amounts of the modified polypeptide and the radiocomplex are administered in different compositions.
- the term “therapeutically effective amount” refers to an amount of an active ingredient or component that elicits the desired biological or medicinal response in a subject.
- a therapeutically effective amount can be determined empirically and in a routine manner, in relation to the stated purpose. For example, in vitro assays can optionally be employed to help identify optimal dosage ranges. Selection of a particular effective dose can be determined (e.g., via clinical trials) by those skilled in the art based upon the consideration of several factors, including the disease to be treated or prevented, the symptoms involved, the patient's body mass, the patient's immune status and other factors known by the skilled artisan.
- Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the terms “treat,” “treating,” and “treatment” are all intended to refer to an amelioration or reversal of at least one measurable physical parameter related to a disease, disorder, or condition in which administration of a radioactive metal ion would be beneficial, such as a neoplastic disease or disorder, which is not necessarily discernible in the subject, but can be discernible in the subject.
- the terms “treat,” “treating,” and “treatment,” can also refer to causing regression, preventing the progression, or at least slowing down the progression of the disease, disorder, or condition.
- “treat,” “treating,” and “treatment” refer to an alleviation, prevention of the development or onset, or reduction in the duration of one or more symptoms associated with the disease, disorder, or condition in which administration of a radioactive metal ion would be beneficial, such as a neoplastic disease or disorder.
- “treat,” “treating,” and “treatment” refer to prevention of the recurrence of the disease, disorder, or condition.
- “treat,” “treating,” and “treatment” refer to an increase in the survival of a subject having the disease, disorder, or condition.
- “treat,” “treating,” and “treatment” refer to elimination of the disease, disorder, or condition in the subject.
- neoplastic diseases or disorders include, but are not limited to, a disseminated cancer, a solid tumor cancer, a hypertrophy, a coronary disease, or a vascular occlusive disease, a disease or disorder associated with an infected cell, a microbe or a virus, or a disease or disorder associated with an inflammatory cell, such as rheumatoid arthritis (RA).
- a disseminated cancer a solid tumor cancer, a hypertrophy, a coronary disease, or a vascular occlusive disease
- a disease or disorder associated with an infected cell such as rheumatoid arthritis (RA).
- RA rheumatoid arthritis
- the term “subject” refers to an animal, and preferably a mammal.
- the subject is a mammal including a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, rabbit, guinea pig, marmoset or mouse) or a primate (e.g., a monkey, chimpanzee, or human).
- a non-primate e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, rabbit, guinea pig, marmoset or mouse
- a primate e.g., a monkey, chimpanzee, or human.
- the subject is a human.
- any dosing schedule of the modified polypeptide and the radiocomplex can be used in view of the present disclosure.
- the radiocomplex can be administered any time after the modified antibody is administered.
- compositions used in the treatment of a neoplastic disease or disorder can be used in combination with other agents that are effective for treatment of related neoplastic diseases or disorders.
- a first therapy e.g., a composition described herein
- a first therapy can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy to
- the invention in another general aspect, relates to a theranostic agent comprising a radiolabeled antibody prepared by a method of the invention and a pharmaceutically acceptable carrier, wherein the immunological properties of the radiolabeled antibody are preserved.
- theranostic refers to the ability to provide either of diagnostic and therapeutic functions.
- a theranostic agent provides both diagnostic and therapeutic functions.
- a theranostic agent is an active pharmaceutical agent without diagnostic function.
- a theranostic agent is an agent useful for diagnosis but having no therapeutic function.
- the radiometal ion is a diagnostic emitter, preferably 89 Zr. According to other preferred embodiments, the radiometal ion is a therapeutic emitter, preferably 225 Ac. According to preferred embodiments, the theranostic agent is used to provide both diagnostic and therapeutic functions to a subject in need thereof.
- a combination of the invention is a reaction mixture used to label the polypeptide with the radiometal ion.
- the combination is a pack or kit used to produce a radiolabeled polypeptide, in vitro or in vivo.
- Optionally associated with the combination can be a notice or instructions in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- the combinations encompassed herein can be used in the above methods of labeling a polypeptide with a radiometal ion, or of treating a neoplastic disease or disorder in a subject in need thereof.
- the invention provides also the following non-limiting embodiments.
- Embodiment 1 is a method of labeling a polypeptide with a radiometal ion, the method comprising:
- Embodiment 1a is the method of Embodiment 1, wherein the chelant comprises a macrocycle.
- Embodiment 1b is the method of Embodiment 1, wherein the chelant comprises an open chain ligand.
- Embodiment 2 is the method of Embodiment 1, wherein one of the first and second click reaction partners comprises an alkyne group, and the other click reaction partner comprises an azide.
- Embodiment 3 is the method of Embodiment 2, wherein the first click reaction partner comprises an azide group and the second click reaction partner comprises an alkyne group.
- Embodiment 3a is the method of Embodiment 2 or 3, wherein the alkyne group comprises a terminal alkyne.
- Embodiment 3b is the method of Embodiment 2 or 3, wherein the alkyne group comprises a cyclic alkynes, preferably a cyclooctyne or cyclooctyne derivative.
- Embodiment 3c is the method of Embodiment 3b, wherein the alkyne group comprises bicyclononyne (BCN).
- BCN bicyclononyne
- Embodiment 3d is the method of Embodiment 3b, wherein the alkyne group comprises difluorinated cyclooctyne (DIFO).
- DIFO difluorinated cyclooctyne
- Embodiment 3e is the method of Embodiment 3b, wherein the alkyne group comprises dibenzocyclooctyne (DIBO).
- DIBO dibenzocyclooctyne
- Embodiment 3f is the method of Embodiment 3b, wherein the alkyne group comprises biarylazacyclooctynone (BARAC).
- BARAC biarylazacyclooctynone
- Embodiment 3g is the method of Embodiment 3b, wherein the alkyne group comprises dibenzoazacyclooctyne (DIBAC).
- DIBAC dibenzoazacyclooctyne
- Embodiment 3h is the method of Embodiment 3b, wherein the alkyne group comprises dimethoxyazacyclooctyne (DIMAC).
- DIMAC dimethoxyazacyclooctyne
- Embodiment 3i is the method of Embodiment 3b, wherein the alkyne group comprises dibenzyocyclooctyne (DBCO).
- DBCO dibenzyocyclooctyne
- Embodiment 3j is the method of Embodiment 3b, wherein the alkyne group comprises difluorobenzocyclooctyne (DIFBO).
- DIFBO difluorobenzocyclooctyne
- Embodiment 3k is the method of Embodiment 3b, wherein the alkyne group comprises monobenzocyclooctyne (MOBO).
- MOBO monobenzocyclooctyne
- Embodiment 3l is the method of Embodiment 3b, wherein the alkyne group comprises tetramethoxy DIBO (TMDIBO).
- TMDIBO tetramethoxy DIBO
- Embodiment 3m is the method of any one of Embodiments 2 to 3l, wherein the azide group comprises NHS-azide.
- Embodiment 4 is the method of Embodiment 1, wherein one of the first and second click reaction partners comprises an alkene group, and the other click reaction partner comprises a diene.
- Embodiment 4a is the method of Embodiment 4, wherein the diene comprises a tetrazine or tetrazole group.
- Embodiment 4b is the method of Embodiment 4 or 4a, wherein the alkene group comprises norbornene.
- Embodiment 4c is the method of Embodiment 4 or 4a, wherein the alkene group comprises trans-cyclooctene (TCO).
- TCO trans-cyclooctene
- Embodiment 5 is the method of any one of Embodiments 1 to 4c, wherein the polypeptide is an antibody or an antigen binding fragment thereof.
- Embodiment 6 is the method of Embodiment 5, wherein the antibody is a monoclonal antibody, or an antigen binding fragment thereof.
- Embodiment 6a is the method of any one of Embodiments 1 to 6, wherein the modified polypeptide is obtained by randomly conjugating one or more azide groups to the polypeptide.
- Embodiment 6b is the method of any one of Embodiments 1 to 6, wherein the modified polypeptide is a modified antibody or antigen binding fragment thereof obtained by site specific incorporation of the first click reaction partner.
- Embodiment 6c is the method of Embodiment 6b, wherein the modified antibody or antigen binding fragment thereof is obtained by trimming the antibody or antigen binding fragment thereof with a bacterial endoglycosidase specific for the ⁇ -1,4 linkage between the core GlcNac residue(s) in the Fc-glycosylation site(s) of the antibody to obtain a trimmed antibody or antigen binding fragment thereof, and reacting the trimmed antibody or antigen binding fragment thereof with an azide sugar, preferably UDP-GalNaz azido sugar substrate, in the presence of a sugar transferase, preferably GalT galactosyltransferase.
- an azide sugar preferably UDP-GalNaz azido sugar substrate
- Embodiment 6d is the method of Embodiment 6b, wherein the modified antibody or antigen binding fragment thereof is obtained by deglycosylating the antibody or antigen binding fragment thereof with an amidase to obtain a deglycosylated antibody or antigen binding fragment thereof, and reacting the deglycosylated antibody or antigen binding fragment thereof with an azido amine, preferably 3-azido propylamine, in the presence of a microbial transglutaminase.
- Embodiment 6e is the method of any one of Embodiments 6 to 6d, wherein the antibody is an antibody that binds to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8.
- PSMA prostate-specific membrane antigen
- Embodiment 6f is the method of Embodiment 6e, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 7 is the method of any one of Embodiments 1 to 6d, wherein the radiometal ion is 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 255 Fm, 227 Th, 62 Cu, 64 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, or 111 In.
- the radiometal ion is 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 153 Sm, 159 Gd, 165 Dy,
- Embodiment 7a is the method of any one of Embodiments 1 to 6d, wherein the radiometal ion is 225 Ac.
- Embodiment 7b is the method of any one of Embodiments 1 to 6d, wherein the radiometal ion is 111 In.
- Embodiment 7c is the method of any one of Embodiments 1 to 6d, wherein the radiometal ion is 89 Zr.
- Embodiment 8 is the method of any one of Embodiments 1 to 7c, wherein the chelating moiety is covalently linked to the second click reaction partner via a linker.
- Embodiment 9 is the method of any one of Embodiments 1 to 8, further comprising reacting an electrophile on a side chain, preferably the amino side chain of a lysine on or introduced to the polypeptide, with a sulfhydryl group covalently linked to the first click reaction partner to obtain the modified polypeptide, preferably NHS-azide.
- Embodiment 10 is a method of any one of Embodiments 1 to 9, wherein the modified polypeptide comprises the polypeptide covalently linked, directly or via a linker, to an azide, tetrazine or tetrazole group.
- Embodiment 11 is the method of any one of Embodiments 1 to 10, wherein the chelant comprises a macrocycle, preferably a structure of formula (I):
- each of R 1 , R 2 , R 3 and R 4 is independently CHQCO 2 X, wherein
- Embodiment 12 is the method of any one of Embodiments 1 to 11, wherein the chelating moiety comprises the structure of formula (II):
- Embodiment 12a is the method of any one of Embodiments 1 to 11, wherein the chelating moiety comprises a chelant having an open chain ligand, preferably the chelating moiety having a structure of formula (III):
- Embodiment 12b is the method of any one of Embodiments 1 to 10, wherein the chelating moiety comprises a chelant selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA), deferoxamine (DFO), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N′′,N′′′,N′′′′,N′′′′′-hexaacetic acid (HEHA), 1,4,7,10,13-pentaazacyclopentanadecane-N,N′,N′′,N′′′, N′′′′-pentaacetic acid (PEPA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) Macropa (Thiele et al., An Eighteen-Membered Macrocyclic Ligand for Actinium-225
- TETA 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid
- DOTPA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrapropionic acid
- TETPA 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid
- DOTMP 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid
- Embodiment 12c is the method of Embodiment 12b, wherein the chelant comprises 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA).
- DOTA 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid
- Embodiment 12d is the method of Embodiment 12b, wherein the chelant comprises deferoxamine (DFO).
- DFO deferoxamine
- Embodiment 13 is a method of labeling a polypeptide, preferably an antibody or an antigen binding fragment thereof, with a radiometal ion, preferably 225 Ac, 111 In or 89 Zr, the method comprising:
- each of R 1 , R 2 , R 3 and R 4 is independently CHQCO 2 X, wherein
- Q is independently hydrogen, C 1 -C 4 alkyl or (C 1 -C 2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C 1 -C 4 alkyl
- Z is (CH 2 ) n Y, wherein
- Embodiment 13a is the method of Embodiment 13, wherein the chelant comprises 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA).
- DOTA 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid
- Embodiment 13b is the method of Embodiment 13, wherein the chelating moiety comprises the structure of formula (II):
- Embodiment 13d is a method of labeling a polypeptide, preferably an antibody or an antigen binding fragment thereof, with a radiometal ion, preferably 225 Ac, 111 In or 89 Zr, the method comprising:
- Embodiment 14 is the method of any one of Embodiments 13 to 13c, wherein the chelant is covalently linked to the alkyne or an alkene group via a linker.
- Embodiment 15 is the method of any one of Embodiments 13 to 14, further comprising reacting an electrophile on a side chain, preferably the amino side chain of a lysine on or introduced to the polypeptide, preferably the antibody or antigen binding fragment thereof, with a sulfhydryl group covalently linked to the azide, preferably NHS-azide, to obtain the modified polypeptide or antibody or antigen binding fragment thereof.
- an electrophile on a side chain preferably the amino side chain of a lysine on or introduced to the polypeptide, preferably the antibody or antigen binding fragment thereof
- a sulfhydryl group covalently linked to the azide, preferably NHS-azide
- Embodiment 16 is the method of any one of Embodiments 13 to 15, wherein the polypeptide, preferably antibody or antigen binding fragment thereof, is covalently linked to the azide via a linker.
- Embodiment 17 is the method of Embodiment 13, wherein the polypeptide is an antibody or antigen binding fragment thereof, the radiometal ion is 225 Ac, 111 In or 89 Zr, and the chelating moiety comprises the structure of formula (II):
- Embodiment 17a is the method of Embodiment 13c, wherein the polypeptide is an antibody or antigen binding fragment thereof, the radiometal ion is 225 Ac, 111 In or 89 Zr, and the chelating moiety comprises the structure of formula (III):
- Embodiment 17 is the method of any one of Embodiments 13 to 17a, wherein the polypeptide is an antibody that binds to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8.
- PSMA prostate-specific membrane antigen
- Embodiment 17c is the method of Embodiment 17b, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 18 is a method of dually labeling a polypeptide with two radiometal ions, the method comprising:
- Embodiment 19 is the method of Embodiment 18, wherein one of the first and second click reaction partners comprises an alkyne group, and the other of the first and second click reaction partner comprises an azide, and wherein one of the third and fourth click reaction partners comprises an alkene group, and the other of the third and fourth click reaction partner comprises a diene.
- Embodiment 20 is the method of Embodiment 18 or 19, wherein the first or second radiometal ion is a diagnostic emitter, and the other is a therapeutic emitter.
- Embodiment 21 is the method of Embodiment 18 or 19, wherein both the first and second radiometal ions are therapeutic emitters.
- Embodiment 21a is the method of Embodiment 20 or 21, wherein the diagnostic emitter is 62 Cu, 64 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, or 111 In.
- Embodiment 21b is the method of any one of Embodiments 20 to 21a, wherein the therapeutic emitter is 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 255 Fm or 227 Th.
- the therapeutic emitter is 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211
- Embodiment 22 is a pharmaceutical composition comprising a radiolabeled polypeptide prepared by a method of any one of Embodiments 1 to 21b and a pharmaceutically acceptable carrier.
- Embodiment 23 is a method of treating or diagnosing a disease or disorder, particularly a neoplastic disease or disorder, in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of Embodiment 22.
- Embodiment 24 is the method of Embodiment 23, wherein the pharmaceutical composition comprises two compositions to be administered sequentially, the first comprising the modified polypeptide, and the second comprising the radiocomplex or radiocomplexes.
- Embodiment 25 is a theranostic agent comprising a radiolabeled antibody prepared by a method of any one of Embodiments 1 to 21b and a pharmaceutically acceptable carrier, wherein the immunological properties of the radiolabeled antibody are preserved.
- Embodiment 26 is the theranostic agent of Embodiment 25, wherein the radiometal ion is a diagnostic emitter, preferably 89 Zr.
- Embodiment 27 is the theranostic agent of Embodiment 25, wherein the radiometal ion is a therapeutic emitter, preferably 225 Ac.
- Embodiment 27a is the theranostic agent of Embodiment 25, wherein the radiometal ion is 111 In.
- Embodiment 27b is the theranostic agent of any one of Embodiments 25 to 27a, wherein the polypeptide is antibody that binds to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8.
- PSMA prostate-specific membrane antigen
- Embodiment 27c is the theranostic agent of Embodiment 27b, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 27d is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (IV):
- Embodiment 27e is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (V):
- Embodiment 27f is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (VI):
- Embodiment 27g is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (VII):
- Embodiment 27h is the theranostic agent of any one of Embodiments 25 to 27g, wherein the radiolabeled antibody has a chelator:antibody ratio (CAR) of less than 3.
- CAR chelator:antibody ratio
- Embodiment 27i is the theranostic agent of any one of Embodiments 25 to 27h, wherein the radiolabeled antibody has a chelator:antibody ratio (CAR) of 2.
- CAR chelator:antibody ratio
- Embodiment 28 is a combination, preferably a kit, comprising:
- Embodiment 28a is the combination or kit of Embodiment 28, wherein the chelant comprises a macrocycle.
- Embodiment 28b is the combination or kit of Embodiment 28, wherein the chelant comprises an open chain ligand.
- Embodiment 29 is the combination or kit of Embodiment 28, which is to be used for labeling the polypeptide with the radiometal ion via a reaction between the first and second click reaction partners in vitro.
- Embodiment 30 is the combination or kit of Embodiment 28, which is to be used for labeling the polypeptide with the radiometal ion via a reaction between the first and second click reaction partners in vivo.
- Embodiment 31 is a composition comprising a modified polypeptide comprising a polypeptide covalently linked to a first click reaction partner.
- Embodiment 32 is a composition comprising a radiocomplex comprising a radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner.
- Embodiment 32a is the composition of Embodiment 32, wherein the chelant comprises a macrocycle.
- Embodiment 32b is the composition of Embodiment 32, wherein the chelant comprises an open chain ligand.
- Embodiment 33 is the combination or kit of any one of Embodiments 28 to 30 or the composition of Embodiment 31 or 32, wherein the polypeptide is an antibody or an antigen binding fragment thereof.
- Embodiment 33a is the combination or kit or the composition of Embodiment 33, wherein the antibody is capable of binding to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8.
- PSMA prostate-specific membrane antigen
- Embodiment 33b is the combination or kit or the composition of Embodiment 33a, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 33c is the combination or kit or the composition of Embodiment 33a or 33b, wherein the antibody or antigen binding fragment thereof is covalently linked to an azide group.
- Embodiment 33d is the combination or kit or the composition of Embodiment 33c, wherein the antibody or antigen binding fragment thereof is covalently linked to the azide group randomly.
- Embodiment 33e is the combination or kit or the composition of Embodiment 33c, wherein the antibody or antigen binding fragment thereof is covalently linked to the azide group site specifically.
- Embodiment 33f is the combination or kit or the composition of Embodiment 33e, wherein the antibody or antigen binding fragment thereof is covalently linked to the azide group via a method comprising: trimming the antibody or antigen binding fragment thereof with a bacterial endoglycosidase specific for the ⁇ -1,4 linkage between the core GlcNac residue(s) in the Fc-glycosylation site(s) of the antibody to obtain a trimmed antibody or antigen binding fragment thereof, and reacting the trimmed antibody or antigen binding fragment thereof with an azide sugar, preferably UDP-GalNaz azido sugar substrate, in the presence of a sugar transferase, preferably GalT galactosyltransferase.
- an azide sugar preferably UDP-GalNaz azido sugar substrate
- Embodiment 33g is the combination or kit or the composition of Embodiment 33e, wherein the modified antibody or antigen binding fragment thereof is obtained by a method comprising deglycosylating the antibody or antigen binding fragment thereof with an amidase to obtain a deglycosylated antibody or antigen binding fragment thereof, and reacting the deglycosylated antibody or antigen binding fragment thereof with an azido amine, preferably 3-azido propylamine, in the presence of a microbial transglutaminase.
- Embodiment 34 is the combination, kit or composition of any one of Embodiments 33 to 33g, wherein the radiometal ion comprises 225 Ac, 111 In or 89 Zr.
- Embodiment 35 is the combination, kit or composition of Embodiment 34, wherein the chelant comprises a macrocycle, preferably a structure of formula (I):
- each of R 1 , R 2 , R 3 and R 4 is independently CHQCO 2 X, wherein
- Embodiment 36 is the combination, kit or composition of Embodiment 35, wherein the electrophilic or nucleophilic moiety is covalently linked to the alkyne group via a linker.
- Embodiment 37 is the combination, kit or composition of Embodiment 35 or 36, wherein the chelating moiety comprises a structure of formula (II):
- Embodiment 37a is the combination, kit or composition of Embodiment 34, wherein the chelating moiety comprises a chelant having an open chain ligand, preferably the chelating moiety comprises a structure of formula (III):
- Embodiment 38 is the combination, kit or composition of any one of Embodiments 34 to 37, wherein the polypeptide is covalently linked to the azide via a linker.
- Embodiment 39 is a method of treating or diagnosing a disease or disorder, particularly a neoplastic disease or disorder, in a subject in need thereof, comprising administering to the subject the theranostic agent of any one of Embodiments 25-27d, or the combination of anyone of Embodiments 28 and 33 to 38.
- Embodiment 40 is a method of treating or diagnosing a disease or disorder, particularly a neoplastic disease or disorder, in a subject in need thereof, comprising administering to the subject the composition of Embodiment 31 and the composition of Embodiment 32, preferably the polypeptide is an antibody.
- a human IgG4 antibody that binds to human prostate-specific membrane antigen (PSMA), referred to herein as “anti-PSMA mAb” with designation “PSMB127”, has a heavy chain (HC) CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8, and has a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Anti-PSMA mAb was expressed and purified using standard chromatography methods.
- a human IgG4 S228P/F234A/L235A (IgG4-PAA) antibody isotype control for the anti-PMSA mAb referred to herein as “control mAb”, has a HC sequence of SEQ ID NO: 1 and a LC sequence of SEQ ID NO: 2.
- the commercial antibodies trastuzumab (Herceptin), cetuximab (Erbitux), pertuzumab (Perjeta), and panitumumab (Vectibix) were purchased from Roche, Lilly, Roche, and Amgen respectively.
- Mouse anti-human Her2 mAb was obtained from BioXCell (catalog #BE0277). Trastuzumab, pertuzumab, and anti-human Her2 mAb bind to human Her2. Cetuximab and panitumumab bind to human EGFR.
- a stock solution of the antibody (1-10 mg/mL) in 10 mM sodium acetate pH 5.2, phosphate-buffered saline pH 7, or other compatible buffer was mixed with 20% (v/v) of 1 M sodium carbonate buffer pH 9 to a final pH of ⁇ 9.
- NHS-PEG4-azide (Thermo catalog #26130) was dissolved in DMSO to a final concentration of 100 mM, and 0.2% (v/v) of the stock was added to produce a molar excess of ⁇ 3-10 relative to the mAb.
- the reaction was incubated at 22° C. for 10 minutes followed by quenching with the addition of 1 M Tris pH 7.5 to a final concentration of 50 mM Tris.
- the azide-mAb conjugate was purified and exchanged into a compatible buffer (PBS; 20 mM HEPES 150 mM, NaCl pH 7.5; or 10 mM sodium acetate pH 5.2) using a method such as Zeba desalting columns with 7K MW cutoff (Thermo), dialysis; standard protein A affinity chromatography; or another compatible method. After purification, the conjugate was concentrated to 10-20 mg/mL using Amicon concentrators with 50K MW cutoff (Millipore).
- PBS 20 mM HEPES 150 mM, NaCl pH 7.5; or 10 mM sodium acetate pH 5.2
- a method such as Zeba desalting columns with 7K MW cutoff (Thermo), dialysis; standard protein A affinity chromatography; or another compatible method.
- the conjugate was concentrated to 10-20 mg/mL using Amicon concentrators with 50K MW cutoff (Millipore).
- the chelator:antibody ratio was determined by LC/MS analysis with an Agilent G6224 MS-TOF instrument equipped with an Agilent PLRP-S column (300-Angstrom, 2.1 ⁇ 150 mm; catalog #PL1912-3301) (Table 1). The mass spectrum was deconvoluted using the maximum entropy algorithm over the m/z range 2000-3200 for the masses 140-170 kDa.
- Analytical SEC was performed to determine the oligomeric state of the antibodies and antibody conjugates and ensure that the conjugation process had not led to aggregation.
- Non-Antibody Polypeptides are non-Antibody Polypeptides:
- human holo-Transferrin was purchased from R&D Systems (catalog #2914-HT) and dissolved in water to 10 mg/mL.
- EGF human epidermal growth factor (EGF) was purchased from Sino Biological (catalog #10605-HNAE).
- NHS-PEG4-azide (Thermo catalog #26130) was dissolved in DMSO to a final concentration of 100 mM, and 0.2% (v/v) of the stock was added to produce a molar excess of ⁇ 3-10 relative to the protein.
- the reaction was incubated at 22° C. for 10 minutes followed by quenching with 1 M Tris pH 7.5 to a final concentration of 50 mM.
- the conjugation efficiency is shown in Table 2.
- Antibody glycans were trimmed with GlycINATOR (Genovis), a bacterial endoglycosidase specific for the ⁇ -1,4 linkage between the core GlcNac residues in the Fc-glycosylation site(s) leaving the inner most GlcNAc intact on the Fc, which can then be used for site-specific incorporation of azido sugars. More specifically, immobilized GlycINATOR on agarose beads packed into a column (Genovis) was equilibrated in Tris-buffered saline pH 7.4 (TBS). 1 mL of mAb at 5-10 mg/mL was added to the resin and incubated on a rocker for 1 hour at RT.
- GlycINATOR Genovis
- TBS Tris-buffered saline pH 7.4
- mAb was eluted by spinning at 100 ⁇ g for 1 minute.
- the column was eluted 3 more times with 0.5 mL TBS.
- the elutions containing trimmed mAb were pooled, and the supplied buffer additive (Genovis) was added along with UDP-GalNaz azido sugar substrate and GalT galactosyltransferase enzyme.
- the reaction was incubated overnight at 30° C.
- the final azido mAb was purified using a mAb Select column (GE) on an AKTA Avant instrument. Azide modification was confirmed by LC-MS with the CAR determined to be exactly 2.
- Azido groups were installed site-specifically on the antibody at positions Gln295 essentially as described (Dennler et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconj Chem 2014 Mar. 19; 25(3): p. 569-78).
- Anti-PSMA mAb was deglycosylated with Rapid PNGase F (New England Biolabs), an amidase which cleaves between the innermost GlcNAc and asparagine residues of high mannose, hybrid, and complex oligosaccharides and allows for complete deglycosylation and release of all N-glycans, including N-glycans from both conserved (e.g., Fc Asn297) and non-conserved (e.g., Fab N-glycans) glycosylation sites.
- Rapid PNGase F New England Biolabs
- DBCO-amine (3-Amino-1-[(5-aza-3,4:7,8-dibenzocyclooct-1-yne)-5-yl]-1-propanone, Sigma) was reacted with the DOTA-GA anhydride and the product was purified by reverse-phase HPLC.
- 111 InCl3 in 0.05 M HCl was purchased from GE Healthcare.
- DOTA-GA-DBCO 1 mg/mL in water, 2.5 ⁇ L, 3.4 nmol
- HCl 0.1 N, 5 ⁇ L
- 111 InCl 3 in 0.05 N HCl 5 ⁇ L, 104.3 ⁇ Ci measured in a Capintec CRC-55TW dose calibrator, 0.0022 nmol.
- the pH of the mixture was observed to be ⁇ 5.5 by pH paper.
- the vial was placed on a shake block at 60° C. and 290 rpm for 30 min., and the vial was allowed to cool to room temperature.
- 89 Zr oxalate was purchased from 3D Imaging.
- DFO-DBCO was purchased from Macrocyclics (Plano, Tex. catalog #B-773), dissolved in DMSO to 0.5 mg/mL, and diluted in water to 25 ⁇ g/mL.
- the chelate was analyzed by spotting 0.5 ⁇ L of the reaction on a TLC Green strip (Biodex) and eluting with 20% NaCl. After elution, the strip was scanned with a PerkinElmer Cyclone Plus phosphor imager to ensure that the majority of the Zr-89 remained at the baseline, indicating chelation by DFO-DBCO.
- the cartridge was in turn washed with de-ionized water (20 ml) to remove excess oxalic acid followed by elution of 89 ZrCl 4 off the column with 1.0 M HCl(aq.) (100 ⁇ L each) to afford a total volume of 400 ⁇ L with recovery of 248 ⁇ Ci (86%), the majority of activity being in fraction 3.
- de-ionized water 20 ml
- 89 ZrCl 4 100 ⁇ L each
- the combined aliquots were then evaporated to dryness.
- the yield of 89 Zr-DOTA-GA-DBCO complex was determined to be 98% by SPC25 column (Sigma Aldrich part number SPC25120-50G) eluted with 1% NH 4 OH solution. Un-chelated 89 Zr stays on the column, while 89 Zr-DOTA-GA-DBCO complex is eluted out.
- FIGS. 1 and 2 See FIGS. 1 and 2 for schematics of schematics of radiolabeling antibodies according to methods of the invention.
- PD-10 column GE Healthcare
- the reaction vial was washed with NaOAc buffer (0.2 mL ⁇ 3), the washings were pipetted into the reservoir of the PD-10 column, and the eluate was collected.
- NaOAc buffer was continuously applied into the reservoir of the PD-10 column, and the eluate was collected in plastic tubes with each tube collecting ⁇ 1 mL of the eluate, until a total of 10 mL of eluate was collected.
- each fraction collected was assessed by iTLC-SG (Agilent) using citrate-H 2 O-MeOH solution as the mobile phase. Pure fraction(s) were combined to afford final product in 10 mM NaOAc buffer.
- the product solution was analyzed by HPLC for chemical and radiochemical purity. The antibody concentration in the product solution was determined by UV absorption using a standard curve. The activity of the product solution was in turn quantified using a Capintec CRC-55TW dose calibrator.
- a chelation challenge was employed using diethylenetriaminepentaacetic acid (DTPA) as a quality control for a purified product.
- DTPA diethylenetriaminepentaacetic acid
- the two mixtures were placed on a shake block at room temperature and 290 rpm for 30 min.
- the mixture was spotted on iTLC-SG and developed with citrate-H 2 O-MeOH solution as the mobile phase. Under these conditions, free 225 Ac migrates to the solvent front and the bound 225 Ac-mAb stays at the baseline.
- Random or site-specific azide-modified anti-PSMA mAb in 10 mM NaOAc was added to the solution of 111 In-DOTA-GA-DBCO produced as described.
- the reaction solution was gently agitated and allowed to stand still at room temperature for 2 h before passing through a PD-10 column.
- the PD-10 column was pre-conditioned by passing 15 mL of NaOAc buffer, 10 mM, pH 6-6.5, through the column, and the washings were discarded.
- the reaction mixture was then pipetted into the reservoir of the pre-conditioned PD-10 column, and the eluate was collected in plastic tubes.
- the reaction vial was washed with NaOAc buffer (0.2 mL ⁇ 3), the washings were pipetted into the reservoir of the PD-10 column, and the eluate was collected.
- NaOAc buffer was continuously applied into the reservoir of the PD-10 column, and the eluate was collected in plastic tubes with each tube collecting ⁇ 1 mL of the eluate, until a total of 10 mL of eluate was collected.
- PD-10 column GE Healthcare
- Zr-DFO-mAbs purified products were analyzed by HPLC only. These conjugates did not retain Zr-89 upon challenge with DTPA or EDTA. Zr-DOTA-mAbs were challenged with the addition of EDTA to 33 mM and incubated overnight at RT. Conjugates were analyzed after challenge by running over a PD-10 column and found to retain 80% of the radioactivity.
- Radiochemical conversion (% RA conversion; see Tables 3-5) was determined by iTLC-SG (Instant Thin Layer Chromatography (iTLC) using a binderless, glass microfiber chromatography paper impregnated with a silica gel (SG)). % RA conversion values are calculated by dividing the integrated value of the product peak's radio signal (of different retention time of radioactive starting material and byproducts) by the value obtained when integrating all radio signal peaks present between the baseline and solvent front. This fraction of product is then expressed as a percentage conversion.
- iTLC-SG Instant Thin Layer Chromatography (iTLC) using a binderless, glass microfiber chromatography paper impregnated with a silica gel (SG)
- sample solutions containing ⁇ 0.1-1 ⁇ Ci of 22 Ac were spotted on the baseline of an iTLC-SG strip approximately 2 cm from the bottom edge.
- the iTLC-SG strip was developed using a citrate-water-methanol mobile phase (20 mL 0.4 M trisodium citrate/3 mL 2 N HCl/2.3 mL MeOH), allowed to dry at room temperature, and stored for a minimum of 6 h before analysis (reaching secular equilibrium of 225Ac and all daughter nuclides).
- the iTLC-SG was scanned using a Bioscan AR2000 radio-TLC imaging scanner using a 99mTc setting.
- sample solutions containing ⁇ 0.5-2.5 ⁇ Ci of 111 In were spotted on the baseline of an iTLC-SG strip, approximately 2 cm from the bottom edge.
- the iTLC-SG strip was developed using 10 mM sodium EDTA pH 5-6 as the mobile phase and then allowed to dry at room temperature.
- the dried iTLC-SG was scanned using a Bioscan AR2000 radio-TLC imaging scanner using an In-111 setting.
- the % RA conversion was determined by dividing the activity on the product peak by the total activity including the activity in the PD-10 column, as determined by counting with a dose calibrator.
- Radiochemical purity (% RA purity; see Tables 3-4) of Ac-225 and In-111 chelates was determined by SE-HPLC (size exclusion HPLC).
- a Tosoh TSKgel column (G3000SWxl7.8 mm ⁇ 30 cm, 5 um) was used; the column was eluted with DPBS buffer (1 ⁇ , without calcium and magnesium); flow rate: 0.7 mL/min; 20 min run; room temperature.
- HPLC the eluate was collected in pre-numbered vials with each vial collecting 0.5 min or 1 min of eluate fraction.
- the eluate-containing vials were left at room temperature for >6 h to allow 225 Ac reach the secular equilibrium with its daughter nuclides.
- the activity in each vial was then counted in a Capintec CRC-55TW well counter.
- the radio-chromatogram was reconstructed based on the activity in the vials.
- Tosoh TSKgel column (G3000SWxl7.8 mm ⁇ 30 cm, 5 um) was used; the column was eluted with DPBS buffer (lx, without calcium and magnesium); flow rate: 0.7 mL/min; 20 min run; room temperature. Radioactivity detection was accomplished using the above HPLC system and a Perkin Elmer radio flow detector Radiomatic 625TR and equipped with a 0.5 mL flow cell using In-111 setting and Ultima FloTM M cocktail at a flow rate of 1.4 mL/min.
- Tosoh TSKgel column (G3000SWxl7.8 mm ⁇ 30 cm, 5 um) was used. The column was eluted with citrate-buffered saline; flow rate: 1 mL/min; 20 min run; room temperature. Radioactivity detection was accomplished using the above HPLC system and a Beckman flow through detector coupled to a Bioscan Flow Count instrument.
- Random and site-specific azido-mAbs (anti-PSMA mAb, Cetuximab, Panitumumab, Trastuzumab, Pertuzumab) at 1-10 mg/mL were mixed with a 5 ⁇ to 20 ⁇ excess of unchelated DOTA-GA-DBCO and incubated at RT or 37° C. for 1-24 hours.
- mAbs were desalted with Zeba desalt spin columns (Thermo) and concentrated with an Amicon centrifuge concentrator (Millipore), rediluted with buffer and concentrated again to remove any remaining DBCO-DOTA. Complete click reaction of all free azides with DBCO-DOTA was confirmed by LC-MS.
- Random and site-specific anti-PSMA mAb azido-mAbs at 1-10 mg/mL were mixed with a 5 ⁇ to 20 ⁇ excess of unchelated DOTA-GA-DFO and incubated at RT or 37° C. for 1-24 hours.
- mAbs were desalted with Zeba desalt spin columns (Thermo) and concentrated with an Amicon centrifuge concentrator (Millipore), rediluted with buffer and concentrated again to remove any remaining DBCO-DFO. Complete click reaction of all free azides with DBCO-DFO was confirmed by LC-MS.
- Cell binding of azide-modified antibodies, DOTA-DBCO-azide modified antibodies, and DFO-DBCO-azide modified antibodies was compared to the parental mAbs for the conjugates described in Table 1.
- Cell lines expressing the mAb target were treated with antibody or conjugate in a range of a concentrations, and binding was measured by flow cytometry.
- Panitumumab and Cetuximab conjugates were evaluated for binding to EGFR+A431 cells.
- Herceptin and Pertuzumab were evaluated for binding to HER2+ SK-BR-3 cells.
- Anti-PSMA mAb was evaluated for binding to PSMA+C4-2b cells.
- C4-2B cells a human prostate carcinoma cell line
- A431 cells a human epidermoid carcinoma cell line
- SK-BR-3 cells a human breast cancer cell line
- EGFR Receptor negative MOLM-13 Human Acute Myeloid Leukemia suspension cells were maintained in RPMI1640+25 mM Hepes (Gibco) supplemented with 20% Heat Inactivated Fetal Bovine Serum (Gibco). Cells were grown in RPMI1640+25 mM Hepes (Gibco, Waltham, Mass.) with 10% FBS (Gibco, Waltham, Mass.).
- Cells were detached from flask using enzyme free cell dissociation buffer (Gibco, Waltham, Mass.) and strained through a 40 um filter (Falcon). 5 ⁇ 10 4 cells were seeded per well in a 96-well u-bottom plate. Cells were incubated with conjugated antibody or parental antibody diluted in BSA stain buffer (BD Bioscience, San Jose, Calif.) for 1 hr at 4° C. Cells were washed twice with stain buffer. Cells were then incubated in the dark for 30 min at 4° C. with AlexaFluor647 tagged anti-human IgG secondary antibody (Jackson ImmunoResearch Laboratories).
- Adherent cells were detached with Enzyme-Free Cell Dissociation Buffer (Gibco). Detached adherent cells and collected suspension cells were counted and washed with cold Stain Buffer (BD Biosciences). Varying numbers of cells in 200 ⁇ L Stain Buffer were added to microcentrifuge tubes and placed on ice. 0.5 ⁇ Ci of In-111 labeled protein was added to each tube and incubated for 1 hour on ice. Cells were washed with cold PBS (Gibco) to remove unbound antibody and resuspended in 500 ⁇ L cold PBS. Samples were transferred to counting vials, and cell-associated radioactivity was determined by gamma counting (Hidex Automatic Gamma Counter).
- CPM Counts per minute
- FIG. 3A Click labeled In-111 anti-PSMA mAb and In-111 transferrin bound to C4-2B cells with amounts of cell-associated radioactivity increasing with increasing cell number.
- Cells were seeded at 3 ⁇ 10 6 cells per 60 mm dish (Corning) and placed in 37° C. humidified CO 2 incubator overnight. Seeding media was removed and replaced with 2 mL cold Stain Buffer (BD Biosciences). Dishes were then placed on ice. 0.5 ⁇ Ci In-111 labeled antibody was added to each dish and incubated for 1 hour on ice. Cells were washed with cold PBS (Gibco) to remove unbound antibody from the cell surface. At various timepoints cells were assayed for surface membrane bound radioactivity and intracellular radioactivity as described below.
- Stripping Buffer 50 mM glycine, 150 mM NaCl pH 2.7 with pepsin (Amresco) added to 25 ⁇ g/mL was added to cells, and dishes were incubated on ice for 15 minutes. Stripping Buffer was transferred to counting vials. Cells were washed with cold PBS, and washes were transferred to counting vials. Radioactivity was assayed by gamma counting (Hidex Automatic Gamma Counter). Surface membrane bound radioactivity was determined as the sum of the Stripping Buffer+PBS Washes.
- Intracellular radioactivity was assayed by preparing cell lysates: After surface-bound radioactivity was stripped and cells were washed, 1.5 mL 1 M NaOH (Teknova) was added to cells, and dishes were incubated on ice for 5 minutes. Surface-Stripped Cell Lysates were transferred to counting vials. Dishes were washed with cold PBS, and washes were transferred to counting vials. Radioactivity was assayed by gamma counting (Hidex Automatic Gamma Counter). Intracellular radioactivity was determined as the sum of the Surface-Stripped Cell Lysates+PBS Washes.
- CPM from study samples were converted to ⁇ Ci In-111 using CPM value from a linear regression created using known amounts of In-111 labeled mAb.
- mice were injected intravenously with a single dose of anti-PSMA mAb-azide-DOTA- 225 Ac or isotype control, control mAb-azide-DOTA- 225 Ac at a range of activities (10 nCi, 25 nCi, 70 nCi, 200 nCi). Injected dose per mouse was made up to a total of 10 ⁇ g protein with cold antibody. Tumor size and body weight were measured twice-weekly. Animals were euthanized when tumor size exceeded 1,500 mm 3 , or body weight loss exceeded 20%.
- Anti-PSMA mAb-DOTA-Ac-225 shows tumor growth inhibition after a single dose, particularly at the higher radioactive doses, and superior to isotype control at all doses ( FIG. 5A ). All doses of the control mAb radioconjugate had similar survival curves to the vehicle control ( FIG. 5B ; Table 7); the anti-PSMA mAb conjugate showed a clear dose-response with survival increasing with increasing radioactive dose ( FIG. 5C ; Table 7). The study was terminated after 209 days, with 3 mice remaining, all from the anti-PSMA mAb 200 nCi group and showing no detectable tumors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is entitled to priority pursuant to 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62/599,830, filed on 18 Dec. 2017, the disclosure of which is incorporated by reference herein in its entirety.
- This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name “Sequence_Listing”, creation date of Dec. 7, 2018, and having a size of about 13.2 kB. The sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.
- The invention relates to methods for radiolabeling polypeptides, such as antibodies. In particular, the invention relates to methods of using click chemistry to label a polypeptide with a radiometal ion. The invention also relates to pharmaceutical compositions and uses of the radiolabeled polypeptides.
- Alpha particle-emitting radionuclides have great promise for cancer therapy due to their combination of high energy with short-range action, providing the possibility of potent killing that is mostly localized to tumor cells (Kim, Y. S. and M. W. Brechbiel, An overview of targeted alpha therapy. Tumour Biol, 2012. 33(3): p. 573-90). Targeted delivery of alpha-emitters, using an antibody, scaffold protein, small molecule ligand, aptamer, or other binding moiety that is specific for a cancer antigen, provides a method of selective delivery of the radionuclide to tumors to enhance their potency and mitigate off-target effects. In common practice, the binding moiety is attached to a chelator which binds to the alpha-emitting radiometal to produce a radiocomplex. Many such examples use a monoclonal antibody (mAb) as the targeting ligand, to produce what is known as a radioimmunoconjugate.
- Actinium-225 (225Ac) is an alpha-emitting radioisotope that is of particular interest for medical applications (Miederer et al., Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev, 2008. 60(12):71-82). The 10-day half-life of 225Ac is long enough to facilitate radio-conjugate production, but short enough to match the circulation pharmacokinetics of delivery vehicles such as antibodies. As such, 225Ac radioimmunoconjugates are of particular interest. Additionally, 225Ac decays in a series of steps that ultimately emits 4 alpha particles before reaching a stable isotope, 209Bi, thereby increasing the potency. Another radioisotope of interest for medical applications is Lutetium-177 (177Lu), which emits both gamma-irradiation suitable for imaging and medium-energy beta-irradiation suitable for radiotherapy. It has been shown that 177Lu-labeled peptides demonstrate reduced normal tissue damage, and that 177Lu-labeling makes it possible to use a single radiolabeled agent for both therapy and imaging (Kwekkeboom D J, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28: p. 1319-1325). Other radioisotopes that are used for therapeutic applications include, e.g., beta or alpha emitters, such as, e.g., thorium, radium, 32P, 47Sc, 67Cu, 77As, 89Sr, 90Y, 99Tc, 105Rh, 109Pd, 111Ag, 131I, 153Sm, 159Gd, 165Dy, 166Ho, 169Er, 186Re, 188Re, 194Ir, 198Au, 199Au, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 255Fm and 227Th. Other radioisotopes that are used for imaging applications include gamma-emitting radioisotopes, such as, e.g., 62Cu, 64Cu, 67Ga, 68Ga, 86Y, 89Zr, and 111In.
- Previous clinical and pre-clinical programs have largely used 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for actinium chelation. However, it is known that DOTA chelation of actinium can be challenging (Deal, K. A., et al., Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem, 1999. 42(15): p. 2988-92), and often requires either harsh conditions or high levels of DOTA per antibody. As a result, two different approaches—known as the “1-step” and “2-step” radiolabeling methods—have been utilized, each with their own drawbacks.
- The “2-step” method, which includes 2 chemical steps involving actinium, was the first to be developed (McDevitt, M. R., et al., Tumor therapy with targeted atomic nanogenerators. Science, 2001. 294(5546): p. 1537-40). 225Ac was chelated by the bifunctional chelator (BFC) DOTA-isothiocyanate (DOTA-SCN) in high radiochemical yield (˜95%) at pH 4.5-5 using 2 M acetate buffer at 55° to 60° C. for 30 min. Subsequently, the 225Ac-DOTA-SCN was reacted with the targeting antibody to produce the radioimmunoconjugate. The major drawback of the 2-step method is that ˜90% of the SCN fails to survive the labeling conditions, thus ˜90% of the input 225Ac is conjugated to nonreactive forms of DOTA that cannot be conjugated to the antibody. This results in not only low yield (typically only about 10%) and higher costs, but also lowered specific activity that can limit the efficacy of the final conjugate.
- The “1-step” method was developed more recently for actinium (Maguire, W. F., et al., Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for alpha-particle radioimmunotherapy of cancer. J Nucl Med, 2014. 55(9): p. 1492-8). This method has only 1 chemical reaction step involving actinium. The DOTA-SCN was first conjugated to the antibody. The 225Ac was then chelated to the DOTA-mAb under mild conditions (37° C., pH 7.5), achieving up to 80% radiochemical yield. However, it was necessary to conjugate high levels of DOTA (˜10 or more per antibody) to achieve high yields. The high chelator:antibody ratio (CAR), in this case the high DOTA:Ab ratio (DAR), species are more likely to have compromised immunoreactivity; furthermore, though the average DAR may be 10, it is likely that the 225Ac is chelating to populations with ratios even higher than the average. Thus, this method runs the risk of linking the 225Ac to the least active fraction of antibody-chelator conjugates. Furthermore, it is necessary to handle the antibody and DOTA-mAb conjugate under metal-free conditions to avoid chelation of common metals such as iron, zinc and copper, which introduces significant challenges into the production process.
- Click chemistry is a chemical approach introduced by Sharpless in 2001 and describes chemistry tailored to generate substances quickly and reliably by joining small units together. See, e.g., Kolb, Finn and Sharpless Angewandte Chemie International Edition (2001) 40: 2004-2021; Evans, Australian Journal of Chemistry (2007) 60: 384-395). Coupling reactions (some of which may be classified as “click chemistry”) include, but are not limited to, formation of esters, thioesters, amides (e.g., such as peptide coupling) from activated acids or acyl halides; nucleophilic displacement reactions (e.g., such as nucleophilic displacement of a halide or ring opening of strained ring systems); azide-alkyne Huisgen cycloaddition (e.g., 1,3-dipolar cycloaddition between an azide and an alkyne to form a 1,2,3-triazole linker); thiolyne addition; imine formation; Diels-Alder reactions between tetrazines and trans-cyclooctene (TCO); and Michael additions (e.g., maleimide addition).
- Click chemistry reactions between alkynes and azides typically require the addition of a copper catalyst to promote the 1,3-cycloaddition reaction, and are known as copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions. However, click chemistry reactions between cyclooctyne or cyclooctyne derivatives and azides typically do not require the addition of a copper catalyst, and instead proceed via strain-promoted azide-alkyne cycloaddition (SPAAC) (Debets, M. F., et al., Bioconjugation with strained alkenes and alkynes. Acc Chem Res, 2011. 44(9): p. 805-15).
- Site-specificity has become a key area of focus in the antibody-drug conjugate (ADC) field (Agarwal, P. and C. R. Bertozzi, Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem, 2015. 26(2): p. 176-92), as it has been demonstrated that both efficacy and safety of ADCs can be increased with site-specific methods as compared to random conjugation. It is thought that similar safety and efficacy benefits could be achieved for radioimmunoconjugates.
- As indicated above, there remains a need in the art for efficient methods of producing stable radioimmunoconjugates with high specific activity and high yield.
- The invention satisfies this need by providing methods for using click chemistry to radiolabel polypeptides, such as antibodies. In a method of the invention, an azide-modified antibody and a radiocomplex comprising a radiometal ion associated with a chelating moiety comprising an alkyne group are used in a click chemistry reaction to produce stable radioimmunoconjugates having a low chelator:antibody ratio (CAR) and high radiochemical yields, while requiring reduced usage of the radioactive metal and only requiring metal-free conditions in the step used to produce the initial radiocomplex. Methods of the invention simplify previous methods for producing radioimmunoconjugates with increased safety, efficacy and uniformity.
- In one general aspect, the invention relates to a method of labeling a polypeptide with a radiometal ion, the method comprising:
-
- a. providing a modified polypeptide comprising the polypeptide covalently linked to a first click reaction partner;
- b. providing a radiocomplex comprising the radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner; and
- c. contacting the modified polypeptide with the radiocomplex under a condition to allow the first click reaction partner to react with the second click reaction partner to thereby label the polypeptide with the radiometal ion.
- In another general aspect, the invention relates to a pharmaceutical composition comprising a radiolabeled polypeptide prepared by a method of the invention and a pharmaceutically acceptable carrier.
- In another general aspect, the invention relates to a method of treating a neoplastic disease or disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the invention.
- In another general aspect, the invention relates to a combination or kit comprising:
-
- a. a modified polypeptide comprising a polypeptide covalently linked to a first click reaction partner; and
- b. a radiocomplex comprising a radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner;
- wherein the combination or kit is to be used for labeling the polypeptide with the radiometal ion.
- In other general aspects, the invention relates to a therapeutic or diagnostic agent (“theranostic agent”) comprising a radiolabeled polypeptide prepared by a method of the invention.
- The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. It should be understood that the invention is not limited to the precise embodiments shown in the drawings.
- In the drawings:
-
FIG. 1 shows a schematic of radiolabeling an antibody according to a method of the invention; random conjugation is shown in the figure, and a similar radiolabeling scheme is used when the azides are conjugated to the monoclonal antibody (mAb) site-specifically; -
FIG. 2 shows a synthesis scheme of an improved two-step preparation of 89Zr-DOTA-mAb via click chemistry according to an embodiment of the application; -
FIG. 3 shows cell binding of In-111 radioimmunoconjugates: bound radioactivity increases with increasing cell number; in particular: -
FIG. 3A shows the binding to the human prostate cancer cell line C4-2B (PSMA+, Transferrin receptor+) by a PSMA-binding antibody (“PSMB127”) In-111 radioimmunoconjugate and a human transferrin In-111 radioconjugate according to embodiments of the application; and -
FIG. 3B shows the binding to the human epidermoid carcinoma cancer cell line A431 (EGFR+) by EGFR-binding antibodies cetuximab and panitumumab In-111 radioimmunoconjugates according to embodiments of the application, and the lack of binding of these conjugates to the control (EGFR−) human AML cell line MOLM-13; -
FIG. 4 shows kinetics of cell internalization of In-111 in the human prostate cancer cell line C4-2B treated with a anti-PSMA mAb In-111 radioimmunoconjugate according to an embodiment of the application; surface-bound In-111 rapidly disappeared from the cell surface and was redistributed intracellularly; and -
FIG. 5 shows the results of a mouse tumor xenograft study; mice were implanted with human prostate cancer LNCaP cells; when tumors reached 100 mm3, mice were treated with a single dose of a click radiolabeled anti-PSMA mAb (“PSMB127”) actinium radioconjugate according to an embodiment of the application at a range of activities or the isotype control, a human IgG4 antibody that binds to a viral target absent in this system radioconjugate; in particular: -
FIG. 5A shows the tumor volume for each group; sizes were plotted until under half of the group remained; -
FIG. 5B shows survival curves for control mAb groups; and -
FIG. 5C shows survival curves for anti-PSMA mAb groups. - Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any inventions disclosed or claimed.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms cited herein have the meanings as set in the specification. All patents, published patent applications and publications cited herein are incorporated by reference as if set forth fully herein
- It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise.
- Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term “comprising” can be substituted with the term “containing” or “including” or sometimes when used herein with the term “having”.
- When used herein “consisting of” excludes any element, step, or ingredient not specified in the claim element. When used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any of the aforementioned terms of “comprising”, “containing”, “including”, and “having”, whenever used herein in the context of an aspect or embodiment of the invention can be replaced with the term “consisting of” or “consisting essentially of” to vary scopes of the disclosure.
- As used herein, the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or”, a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or.”
- In an attempt to help the reader of the application, the description has been separated into various paragraphs or sections, or is directed to various embodiments of the application. These separations should not be considered as disconnecting the substance of a paragraph or section or embodiments from the substance of another paragraph or section or embodiments. To the contrary, one skilled in the art will understand that the description has broad application and encompasses all the combinations of the various sections, paragraphs and sentences that can be contemplated. The discussion of any embodiment is meant only to be exemplary and is not intended to suggest that the scope of the disclosure, including the claims, is limited to these examples.
- Click Radiolabeling of Polypeptides
- In contrast to known procedures, methods of the present invention provide for an improved method for the production of radioimmunoconjugates that are suitable, for example, for medicinal applications in subjects, e.g., humans, in need thereof. In particular, methods described herein address the major limitations of current methods by providing processes for both high yield chelation of metal ions, including but not limited to, 225Ac, 111In and 89Zr, and for low DAR. The invention allows for the production of a single batch of azide-labeled polypeptides, such as azide-mAb conjugate that can then be used for the production of a radiolabeled diagnostic (e.g., when labeled with 89Zr or 111In) or therapeutic (e.g., when labeled with 225Ac) purposes, in which the radiolabel is attached at the same site(s) within the batch of azide-labeled polypeptides, which can be obtained either by site-specific modification or by random azide conjugation. For example, in the case of random azide conjugation, samples of a batch of azide-labeled polypeptides comprising a single distribution of azide-modified sites can be radiolabeled for different purposes using click chemistry of the invention.
- A method of the invention, which relies on click chemistry and is referred to as “click radiolabeling”, involves (1) obtaining a modified polypeptide, such as an antibody, that includes a first click chemistry reaction partner, e.g. an azide moiety; (2) obtaining a radiocomplex comprising a radiometal ion, e.g., 225Ac, 111In or 89Zr, associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently liked to a second click chemistry reaction partner, e.g. an alkyne group, such as DOTA-dibenzocyclooctyne (DOTA-DBCO) or deferoxamine-DBCO (DFO-DBCO); and (3) conducting a reaction between the click chemistry reaction partners of the modified peptide and the radiocomplex, such as a strain-promoted alkyne-azide cycloaddition (SPAAC) between the azide moiety and the alkyne group.
- A method of the invention allows chelation of the radioactive metal under low or high pH and/or high temperature conditions to maximize efficiency, which can be accomplished without the risk of inactivating the alkyne reaction partner. The efficient chelation and efficient SPAAC reaction between azido-mAb and the radiocomplex allows radioimmunoconjugates to be produced with high radiochemical yield even with low azide:mAb ratios. In a method of the invention, the only step in which trace metals must be excluded is the radiometal ion chelation to the chelating moiety; the antibody production, purification, and conjugation steps do not need to be conducted under metal free conditions.
- As used herein, the term “click chemistry” refers to a chemical philosophy introduced by Sharpless, describing chemistry tailored to generate covalent bonds quickly and reliably by joining small units comprising reactive groups together (see Kolb, et al., supra). Click chemistry does not refer to a specific reaction, but to a concept including, but not limited to, reactions that mimic reactions found in nature. In some embodiments, click chemistry reactions are modular, wide in scope, give high chemical yields, generate inoffensive byproducts, are stereospecific, exhibit a large thermodynamic driving force to favor a reaction with a single reaction product, and/or can be carried out under physiological conditions. In some embodiments, a click chemistry reaction exhibits high atom economy, can be carried out under simple reaction conditions, uses readily available starting materials and reagents, uses no toxic solvents or uses a solvent that is benign or easily removed, such as water, and/or provides simple product isolation by non-chromatographic methods, such as crystallization or distillation. In certain embodiments, the click chemistry reaction is a Huisgen cycloaddition or the 1,3-dipolar cycloaddition between an azide (—N3) and an alkyne, or an alkyne moiety, to form a 1,2,4-triazole linker.
- In a general aspect, the invention relates to a method of labeling a polypeptide, an aptamer, or a small molecule ligand with a radiometal ion, the method comprising:
-
- a. providing a modified polypeptide comprising the polypeptide covalently linked to a first click reaction partner;
- b. providing a radiocomplex comprising the radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner; and
- c. contacting the modified polypeptide with the radiocomplex under a condition to allow the first click reaction partner to react with the second click reaction partner to thereby label the polypeptide with the radiometal ion.
- As used herein, the term “polypeptide” refers to a polymer composed of amino acid residues, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof linked via peptide bonds. The term refers to a polypeptide of any size, structure, or function. Typically, a polypeptide is at least three amino acids long. A polypeptide can be naturally occurring, recombinant, or synthetic, or any combination thereof. Synthetic polypeptides can be synthesized, for example, using an automated polypeptide synthesizer. According to preferred embodiments, the polypeptide is an antibody, preferably a monoclonal antibody, or a fragment thereof, such as an antigen-binding fragment thereof. According to preferred embodiments, the antibody or fragment thereof is specific for a cancer antigen. According to other embodiments, the polypeptide is an engineered domain or a scaffold protein.
- As used herein, the term “antibody” or “immunoglobulin” is used in a broad sense and includes immunoglobulin or antibody molecules including polyclonal antibodies, monoclonal antibodies including murine, human, human-adapted, humanized and chimeric monoclonal antibodies, and antigen-binding fragments thereof.
- In general, antibodies are proteins or peptide chains that exhibit binding specificity to a specific antigen, referred to herein as a “target”. Antibody structures are well known. Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub-classified as the isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4. Accordingly, the antibodies of the invention can be of any of the five major classes or corresponding sub-classes. Preferably, the antibodies of the invention are IgG1, IgG2, IgG3 or IgG4. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains. Accordingly, the antibodies of the invention can contain a kappa or lambda light chain constant domain. According to particular embodiments, the antibodies of the invention include heavy and/or light chain constant regions from mouse antibodies or human antibodies. Each of the four IgG subclasses has different biological functions known as effector functions. These effector functions are generally mediated through interaction with the Fc receptor (FcγR) or by binding C1q and fixing complement. Binding to FcγR can lead to antibody dependent cell mediated cytolysis, whereas binding to complement factors can lead to complement mediated cell lysis. An antibody useful for the invention can have no or minimal effector function, but retain its ability to bind FcRn.
- As used herein, the term “antigen-binding fragment” refers to an antibody fragment such as, for example, a diabody, a Fab, a Fab′, a F(ab′)2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv′), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), a single domain antibody (sdab) an scFv dimer (bivalent diabody), a multispecific antibody formed from a portion of an antibody comprising one or more CDRs, a camelized single domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not comprise a complete antibody structure. An antigen-binding fragment is capable of binding to the same antigen to which the parent antibody or a parent antibody fragment binds. As used herein, the term “single-chain antibody” refers to a conventional single-chain antibody in the field, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to about 20 amino acids. As used herein, the term “single domain antibody” refers to a conventional single domain antibody in the field, which comprises a heavy chain variable region and a heavy chain constant region or which comprises only a heavy chain variable region.
- As used herein, the term “scaffold” or “scaffold protein” refers to any protein that has a target binding domain and that can bind to a target. A scaffold contains a “framework”, which is largely structural, and a “binding domain” which makes contact with the target and provides for specific binding. The binding domain of a scaffold need not be defined by one contiguous sequence of the scaffold. In certain cases, a scaffold may be part of larger binding protein, which, itself, may be part of a multimeric binding protein that contains multiple scaffolds. Certain binding proteins may be bi- or multi-specific in that they can bind to two or more different epitopes. A scaffold can be derived from a single chain antibody, or a scaffold may be not antibody-derived.
- Polypeptides of the invention can be covalently linked to a first click reaction partner using any method for chemical or enzymatic modification of a polypeptide known to those skilled in the art in view of the present disclosure. Amine-reactive groups that react with primary amines that exist at the N-terminus of each polypeptide chain and in the side-chain of lysine residues can be used in methods for random modification of polypeptides. Examples of amine-reactive groups suitable for use in the invention include, but are not limited to, N-hydroxy succinimide (NHS), substituted NHS, such as sulfo-NHS, isothiocyanate, and tetra- and per-fluoro phenyl ester. Thiol-reactive groups that react with thiols, or sulfhydryls, that exist in the side-chain of cysteine residues can be used in methods for random modification of polypeptides. Examples of thiol-reactive groups suitable for use in the invention include, but are not limited to, maleimide, haloacetyl and phenyloxadiazole sulfone. According to preferred embodiments, a modified polypeptide is obtained by reacting a side chain, preferably the amino side chain of a lysine, with an electrophile covalently linked to the first click reaction partner (e.g. NHS-azide).
- A method of the invention further allows the production of site-specific radiolabeled polypeptides. The click radiolabeling method of the invention facilitates site-specific production of radioimmunoconjugates by taking advantage of established methods to install azide groups site-specifically on antibodies (Li, X., et al. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl, 2014. 53(28): p. 7179-82; Xiao, H., et al., Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew Chem Int Ed Engl, 2013. 52(52): p. 14080-3). Methods of attaching molecules to proteins or antibodies in a site-specific manner are known in the art, and any method of site-specifically labeling an antibody known to those skilled in the art can be used in the invention in view of the present disclosure. Examples of methods to site-specifically modify antibodies suitable for use in the invention include, but are not limited to, incorporation of engineered cysteine residues (e.g., THIOMAB™), use of non-natural amino acids or glycans (e.g., seleno cysteine, p-AcPhe, formylglycine generating enzyme (FGE, SMARTag™), etc.), and enzymatic methods (e.g., use of glycotransferase, endoglycosidase, microbial or bacterial transglutaminase (MTG or BTG), sortase A, etc.). According to preferred embodiments, the modified polypeptide is an antibody or antigen binding fragment thereof that is obtained by trimming the antibody or antigen binding fragment thereof with a bacterial endoglycosidase specific for the β-1,4 linkage between a core GlcNac residue in a Fc-glycosylation site of the antibody, such as GlycINATOR (Genovis), which leaves the inner most GlcNAc intact on the Fc, allowing for the site-specific incorporation of azido sugars at that site. The trimmed antibody or antigen binding fragment thereof can then be reacted with an azide-labeled sugar, such as UDP-N-azidoacetylgalactosamine (UDP-GalNaz) or UDP-6-azido 6-deoxy GalNAc, in the presence of a sugar transferase, such as GalT galactosyltransferase or GalNAc transferase, to thereby obtain the modified antibody or antigen binding fragment thereof. According to other preferred embodiments, modified polypeptide is an antibody or antigen binding fragment thereof that is obtained by deglycosylating the antibody or antigen binding fragment thereof with an amidase. The resulting deglycosylated antibody or antigen binding fragment thereof can then be reacted with an azido amine, preferably 3-azido propylamine, 6-azido hexylamine, or any azido-linker-amine or any azido-alkyl-amine, such as an azido-polyethylene glycol (PEG)-amine, for example, 0-(2-Aminoethyl)-O′-(2-azidoethyl)tetraethylene glycol, 0-(2-Aminoethyl)-O′-(2-azidoethyl)pentaethylene glycol, O-(2-Aminoethyl)-O′-(2-azidoethyl)triethylene glycol, etc., or in the presence of a microbial transglutaminase to thereby obtain the modified antibody or antigen binding fragment thereof.
- As used herein, the term “aptamer” refers to a single-stranded oligonucleotide (single-stranded DNA or RNA molecule) that can bind specifically to its target with high affinity. The aptamer can be used as a molecule targeting various organic and inorganic materials.
- As used herein, the term “small molecule ligand” refers to a low molecular weight organic compound. Small molecule ligands, as used herein, can refer to compounds that have a size of less than about 1000 daltons, and can be synthesized in the laboratory or found in nature.
- As used herein, the term “click reaction partner” or “click chemistry handle” refers to a reactant or a reactive group that can partake in a click chemistry reaction. A click reaction partner can be a moiety that is rarely found in naturally-occurring biomolecules and is chemically inert towards biomolecules, but, e.g., when reacted with an azide-reactive or alkyne-reactive group, the reaction can take place efficiently under biologically relevant conditions, for example in cell culture conditions, such as in the absence of excess heat or harsh reactants. In general, click chemistry reactions require at least two molecules comprising click reaction partners that can react with each other. Such click reaction partners that are reactive with each other are sometimes referred to herein as click chemistry handle pairs, or click chemistry pairs. In some embodiments, the click reaction partners are an azide and a strained alkyne, e.g. a cyclooctyne, or any other alkyne. In other embodiments, the click reaction partners are reactive dienes and suitable tetrazine dienophiles. For example, trans-cyclooctene, norbornene, or biscyclononene can be paired with a suitable tetrazine dienophile as a click reaction pair. In yet other embodiments, tetrazoles can act as latent sources of nitrile imines, which can pair with unactivated alkenes in the presence of ultraviolet light to create a click reaction pair, termed a “photo-click” reaction pair. In other embodiments, the click reaction partners are a cysteine and a maleimide. For example the cysteine from a peptide (e.g., GGGC) can be reacted with a maleimide that is associated with a chelating agent (e.g., NOTA). Other suitable click chemistry handles are known to those of skill in the art (see, e.g., Spicer et al., Selective chemical protein modification. Nature Communications. 2014; 5: p. 4740). In other embodiments, the click reaction partners are Staudinger ligation components, such as phosphine and azide. In other embodiments, the click reaction partners are Diels-Alder reaction components, such as dienes, such as tetrazine, and alkenes, such as trans-cyclooctene (TCO) or norbornene. Exemplary click reaction partners are described in US20130266512 and in WO2015073746, the relevant description on click reaction partners in both of which are incorporated by reference herein. According to preferred embodiments, one of the first and second click reaction partners comprises an alkyne group, and the other click reaction partner comprises an azide. According to other preferred embodiments, one of the first and second click reaction partners comprises an alkene group, and the other click reaction partner comprises a diene.
- As used herein, the term “alkyne”, “alkyne group” or “alkyne moiety” refers to a functional group comprising a carbon-carbon triple bond. Alkyne moieties include terminal alkynes and cyclic alkynes, preferably terminal alkynes and cyclic alkynes that are reactive with azide groups. A terminal alkyne has at least one hydrogen atom bonded to a triply bonded carbon atom. A cyclic alkyne is a cycloalkyl ring comprising one or more triple bonds. Examples of cyclic alkynes include, but are not limited to, cyclooctyne and cyclooctyne derivatives, such as bicyclononyne (BCN), difluorinated cyclooctyne (DIFO), dibenzocyclooctyne (DIBO), keto-DIBO, biarylazacyclooctynone (BARAC), dibenzoazacyclooctyne (DIBAC), dimethoxyazacyclooctyne (DIMAC), dibenzyocyclooctyne (DBCO), difluorobenzocyclooctyne (DIFBO), monobenzocyclooctyne (MOBO), and tetramethoxy DIBO (TMDIBO). According to preferred embodiments, one of the first and second click reaction partners comprises a cyclic alkyne, preferably DBCO. According to preferred embodiments, the other click reaction partner comprises an azide, preferably NHS-azide.
- As used herein, the term “diene” refers to a compound having two carbon-to-carbon double bonds where these double bonds are conjugated in the 1,3-position. The double bonds of the diene can be either cis or trans. Examples of dienes include, but are not limited to, a tetrazine or a tetrazole group.
- As used herein, the term “alkene”, “alkene group” or “alkene moiety” refers to an unsaturated hydrocarbon molecule that includes a carbon-carbon double bond. According to particular embodiments, an alkene can include from 2 to 100 carbon atoms. Examples of alkenes include, but are not limited to, norbornene and trans-cyclooctene (TCO). According to other preferred embodiments, one of the first and second click reaction partners comprises an alkene group, preferably norbornene or TCO. According to preferred embodiments, the other click reaction partner comprises a diene, preferably a tetrazine or tetrazole group.
- As used herein, the term “covalently linked” means that the polypeptide is attached to the first click reaction partner via at least one covalent linkage, and that the chelant is attached to the second click reaction partner via at least one covalent linkage. The linkage can be direct, i.e. without a linker, or indirect, i.e. via a linker.
- As used herein, the term “linker” refers to a chemical moiety that joins a polypeptide or a chelant to a click reaction partner. Any suitable linker known to those skilled in the art in view of the present disclosure can be used in the invention. The linkers can be, for example, a single covalent bond, a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl moiety, a polyethylene glycol (PEG) linker, a peptide linker, a sugar-based linker, or a cleavable linker, such as a disulfide linkage or a protease cleavage site such as valine-citrulline-PAB.
- As used herein, the term “radiometal ion” or “radioactive metal ion” refers to one or more isotopes of the elements that emit particles and/or photons. Any radioactive metal known to those skilled in the art in view of the present disclosure can be used in the invention. Examples of radioactive metals suitable for use in the invention include, but are not limited to, 32P, 47Sc, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 77As, 86Y, 89Zr, 89Sr, 90Y, 99Tc, 105Rh, 109Pd, 111Ag, 111In, 117Sn, 131I, 153Sm, 159Gd, 165Dy, 166Ho, 169Er, 177Lu, 186Re, 188Re, 194Ir, 198Au, 199Au, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 227Th, and 255Fm. As used herein, the term “diagnostic emitter” refers to a radiometal ion that is useful in diagnostic or imaging applications. Examples of diagnostic emitters include, but are not limited to gamma emitters, such as 62Cu, 64Cu, 67Ga, 68Ga, 86Y, 89Zr, and 111In. As used herein, the term “therapeutic emitter” refers to a radiometal ion that is useful in therapeutic applications. Examples of therapeutic emitters include, but are not limited to, beta or alpha emitters, such as thorium, radium, 32P, 47Sc, 67Cu, 77As, 89Sr, 90Y, 99Tc, 105Rh, 109Pd, 111Ag, 131I, 153Sm, 159Gd, 165Dy, 166Ho, 169Er, 177Lu, 186Re, 188Re, 194Ir, 198Au, 199Au, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 255Fm and 227Th. According to preferred embodiments, the radiometal ion is 225Ac. According to other embodiments, the polypeptide can be labeled with non-metal radiolabels for use in pre-targeting or theranostic applications. Examples of non-metal radiolabels suitable for use in the invention include, but are not limited to, 125 and 18F.
- Radiocomplexes described herein comprise a radiometal ion associated with a chelating moiety. According to embodiments of the invention, the chelating moiety comprises a chelant covalently linked to a click reaction partner, and is sometimes referred to herein as a “bifunctional chelator.”
- As used herein, the term “chelant” or “chelator” refers to a chemical compound to which a radiometal, such as 225Ac, or metal can be chelated via coordinate bonding. Any chelant known to those skilled in the art in view of the present disclosure can be used in the invention. In an embodiment, the chelant comprises a macrocycle. Examples of chelants comprising a macrocycle suitable for use in the invention include, but are not limited to, deferoxamine (DFO), ethylenediaminetetraacetic acid (EDTA), and diethylenetriaminepentaacetic acid (DTPA). In another embodiment, the chelant comprises an open chain ligand. Examples of chelants comprising an open chain ligand suitable for use in the invention include, but are not limited to, 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N″,N′″,N″″,N′″″-hexaacetic acid (HEHA), 1,4,7,10,13-pentaazacyclopentanadecane-N,N′,N″,N′″, N″″-pentaacetic acid (PEPA), Macropa (Thiele et al., An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017 Nov. 13; 56(46): p. 14712-14717), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrapropionic acid (DOTPA), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid (TETPA), and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP). According to preferred embodiments, the chelant comprises a structure of formula (I):
- wherein each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl; and
- Z is (CH2)nY, wherein
- n is 1-10, and
- Y is an electrophilic or nucleophilic moiety covalently linked to the second click reaction partner;
- alternatively, Z is hydrogen; and
- each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl, or an electrophilic or nucleophilic moiety covalently linked to the second click reaction partner.
- According to preferred embodiments, the chelating moiety comprises the structure of formula (II):
- According to preferred embodiments, the chelating moiety comprises the structure of formula (III):
- In an embodiment, the invention relates to a method of labeling a polypeptide with two or more radiometal ions using a method of the invention. For example, a method of dually labeling a polypeptide with two radiometal ions comprises:
-
- a. providing a modified polypeptide comprising the polypeptide covalently linked to a first click reaction partner and a second click reaction partner;
- b. providing a first radiocomplex comprising the first radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a third click reaction partner; and
- c. providing a second radiocomplex comprising the second radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a fourth click reaction partner; and
- d. contacting the modified polypeptide with the first and second radiocomplexes under a condition to allow the first click reaction partner to react with the third click reaction partner, and the second click reaction partner to react with the fourth click reaction partner, to thereby label the polypeptide with the first and second radiometal ions.
- According to preferred embodiments, one of the first and second click reaction partners comprises an alkyne group, and the other of the first and second click reaction partner comprises an azide, and wherein one of the third and fourth click reaction partners comprises an alkene group, and the other of the third and fourth click reaction partner comprises a diene.
- According to preferred embodiments, the first or second radiometal ion is a diagnostic emitter, and the other is a therapeutic emitter. According to other preferred embodiments, both the first and second radiometal ions are therapeutic emitters.
- Conditions for carrying out click chemistry reactions are known in the art, and any conditions for carrying out click chemistry reactions known to those skilled in the art in view of the present disclosure can be used in the invention. Examples of conditions include, but are not limited to, incubating the modified polypeptide and the radiocomplex at a ratio of 1:1 to 1000:1 at a pH of 4 to 10 and a temperature of 20° C. to 70° C.
- Products of click radiolabeling methods of the invention can be analyzed using methods known to those skilled in the art in view of the present disclosure. For example, LC/MS analysis can be used to determine the ratio of the chelator to the labeled polypeptide; analytical size-exclusion chromatography can be used to determine the oligomeric state of the polypeptides and polypeptide conjugates; radiochemical yield can be determined by instant thin layer chromatography (e.g. iTLC-SG), and radiochemical purity can be determined by size-exclusion HPLC. Exemplary methods are described herein, e.g., in the Examples below.
- Pharmaceutical Compositions and Methods of Treatment
- The click radiolabeling method of the invention can be modified into a pre-targeting approach (Kraeber-Bodere, F., et al., A pretargeting system for tumor PET imaging and radioimmunotherapy. Front Pharmacol, 2015. 6: p. 54). First, the azido-mAb is dosed, binds to target cells, and is allowed to clear from circulation over time or removed with a clearing agent. Subsequently, the radiocomplex is administered and undergoes the SPAAC reaction with azido-mAbs bound at the target site, while the remaining unbound radiocomplex clears rapidly from circulation (Deal, K. A., et al., Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem, 1999. 42(15): p. 2988-92). This pre-targeting technique provides a method of enhancing radiometal ion localization at a target site in a subject
- Accordingly, in another general aspect, the invention relates to a pharmaceutical composition comprising a radiolabeled polypeptide prepared by a method of the invention and a pharmaceutically acceptable carrier.
- As used herein, the term “carrier” refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid containing vesicle, microsphere, liposomal encapsulation, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient or diluent will depend on the route of administration for a particular application. As used herein, the term “pharmaceutically acceptable carrier” refers to a non-toxic material that does not interfere with the effectiveness of a composition according to the invention or the biological activity of a composition according to the invention. According to particular embodiments, in view of the present disclosure, any pharmaceutically acceptable carrier suitable for use in an antibody-based, or a radiocomplex-based pharmaceutical composition can be used in the invention.
- According to particular embodiments, the compositions described herein are formulated to be suitable for the intended route of administration to a subject. For example, the compositions described herein can be formulated to be suitable for intravenous, subcutaneous, intramuscular or intratumoral administration.
- According to particular embodiments, the modified polypeptide and the radiocomplex can be administered in the same or different compositions.
- In another general aspect, the invention relates to a method of treating a neoplastic disease or disorder in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of the invention.
- According to particular embodiments, a method of the invention comprises administering a therapeutically effective dose of a pharmaceutical composition of the invention, wherein the composition comprises a radiolabeled polypeptide for targeting cells associated with the neoplastic disease or disorder such that, upon targeting, alpha particles from the 5Ac and daughters thereof are delivered to the targeted cells and cause a cytotoxic effect thereto, thereby treating the neoplastic disease or disorder.
- According to particular embodiments, therapeutically effective amounts of the modified polypeptide and the radiocomplex are administered in different compositions.
- As used herein, the term “therapeutically effective amount” refers to an amount of an active ingredient or component that elicits the desired biological or medicinal response in a subject. A therapeutically effective amount can be determined empirically and in a routine manner, in relation to the stated purpose. For example, in vitro assays can optionally be employed to help identify optimal dosage ranges. Selection of a particular effective dose can be determined (e.g., via clinical trials) by those skilled in the art based upon the consideration of several factors, including the disease to be treated or prevented, the symptoms involved, the patient's body mass, the patient's immune status and other factors known by the skilled artisan. The precise dose to be employed in the formulation will also depend on the route of administration, and the severity of disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- As used herein, the terms “treat,” “treating,” and “treatment” are all intended to refer to an amelioration or reversal of at least one measurable physical parameter related to a disease, disorder, or condition in which administration of a radioactive metal ion would be beneficial, such as a neoplastic disease or disorder, which is not necessarily discernible in the subject, but can be discernible in the subject. The terms “treat,” “treating,” and “treatment,” can also refer to causing regression, preventing the progression, or at least slowing down the progression of the disease, disorder, or condition. In a particular embodiment, “treat,” “treating,” and “treatment” refer to an alleviation, prevention of the development or onset, or reduction in the duration of one or more symptoms associated with the disease, disorder, or condition in which administration of a radioactive metal ion would be beneficial, such as a neoplastic disease or disorder. In a particular embodiment, “treat,” “treating,” and “treatment” refer to prevention of the recurrence of the disease, disorder, or condition. In a particular embodiment, “treat,” “treating,” and “treatment” refer to an increase in the survival of a subject having the disease, disorder, or condition. In a particular embodiment, “treat,” “treating,” and “treatment” refer to elimination of the disease, disorder, or condition in the subject.
- Examples of neoplastic diseases or disorders include, but are not limited to, a disseminated cancer, a solid tumor cancer, a hypertrophy, a coronary disease, or a vascular occlusive disease, a disease or disorder associated with an infected cell, a microbe or a virus, or a disease or disorder associated with an inflammatory cell, such as rheumatoid arthritis (RA).
- As used herein, the term “subject” refers to an animal, and preferably a mammal. According to particular embodiments, the subject is a mammal including a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, rabbit, guinea pig, marmoset or mouse) or a primate (e.g., a monkey, chimpanzee, or human). In particular embodiments, the subject is a human.
- Any dosing schedule of the modified polypeptide and the radiocomplex can be used in view of the present disclosure. In general, when the modified polypeptide and the radiocomplex are administered in different compositions, the radiocomplex can be administered any time after the modified antibody is administered.
- According to particular embodiments, compositions used in the treatment of a neoplastic disease or disorder can be used in combination with other agents that are effective for treatment of related neoplastic diseases or disorders.
- As used herein, the term “in combination,” in the context of the administration of two or more therapies to a subject, refers to the use of more than one therapy. The use of the term “in combination” does not restrict the order in which therapies are administered to a subject. For example, a first therapy (e.g., a composition described herein) can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy to a subject.
- In another general aspect, the invention relates to a theranostic agent comprising a radiolabeled antibody prepared by a method of the invention and a pharmaceutically acceptable carrier, wherein the immunological properties of the radiolabeled antibody are preserved.
- As used herein, the term “theranostic” refers to the ability to provide either of diagnostic and therapeutic functions. In one embodiment, a theranostic agent provides both diagnostic and therapeutic functions. In another embodiment, a theranostic agent is an active pharmaceutical agent without diagnostic function. In yet another embodiment, a theranostic agent is an agent useful for diagnosis but having no therapeutic function.
- According to preferred embodiments, the radiometal ion is a diagnostic emitter, preferably 89Zr. According to other preferred embodiments, the radiometal ion is a therapeutic emitter, preferably 225Ac. According to preferred embodiments, the theranostic agent is used to provide both diagnostic and therapeutic functions to a subject in need thereof.
- Combinations and Kits
- Provided herein is a combination comprising:
-
- a. a modified polypeptide comprising a polypeptide covalently linked to a first click reaction partner; and
- b. a radiocomplex comprising a radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner;
- wherein the combination is to be used for labeling the polypeptide with the radiometal ion.
- According to particular embodiments, a combination of the invention is a reaction mixture used to label the polypeptide with the radiometal ion. According to other embodiments, the combination is a pack or kit used to produce a radiolabeled polypeptide, in vitro or in vivo. Optionally associated with the combination can be a notice or instructions in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. The combinations encompassed herein can be used in the above methods of labeling a polypeptide with a radiometal ion, or of treating a neoplastic disease or disorder in a subject in need thereof.
- The invention provides also the following non-limiting embodiments.
-
Embodiment 1 is a method of labeling a polypeptide with a radiometal ion, the method comprising: -
- a. providing a modified polypeptide comprising the polypeptide covalently linked to a first click reaction partner;
- b. providing a radiocomplex comprising the radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner; and
- c. contacting the modified polypeptide with the radiocomplex under a condition to allow the first click reaction partner to react with the second click reaction partner to thereby label the polypeptide with the radiometal ion.
- Embodiment 1a is the method of
Embodiment 1, wherein the chelant comprises a macrocycle. - Embodiment 1b is the method of
Embodiment 1, wherein the chelant comprises an open chain ligand. -
Embodiment 2 is the method ofEmbodiment 1, wherein one of the first and second click reaction partners comprises an alkyne group, and the other click reaction partner comprises an azide. - Embodiment 3 is the method of
Embodiment 2, wherein the first click reaction partner comprises an azide group and the second click reaction partner comprises an alkyne group. - Embodiment 3a is the method of
Embodiment 2 or 3, wherein the alkyne group comprises a terminal alkyne. - Embodiment 3b is the method of
Embodiment 2 or 3, wherein the alkyne group comprises a cyclic alkynes, preferably a cyclooctyne or cyclooctyne derivative. - Embodiment 3c is the method of Embodiment 3b, wherein the alkyne group comprises bicyclononyne (BCN).
- Embodiment 3d is the method of Embodiment 3b, wherein the alkyne group comprises difluorinated cyclooctyne (DIFO).
- Embodiment 3e is the method of Embodiment 3b, wherein the alkyne group comprises dibenzocyclooctyne (DIBO).
- Embodiment 3f is the method of Embodiment 3b, wherein the alkyne group comprises biarylazacyclooctynone (BARAC).
- Embodiment 3g is the method of Embodiment 3b, wherein the alkyne group comprises dibenzoazacyclooctyne (DIBAC).
- Embodiment 3h is the method of Embodiment 3b, wherein the alkyne group comprises dimethoxyazacyclooctyne (DIMAC).
- Embodiment 3i is the method of Embodiment 3b, wherein the alkyne group comprises dibenzyocyclooctyne (DBCO).
- Embodiment 3j is the method of Embodiment 3b, wherein the alkyne group comprises difluorobenzocyclooctyne (DIFBO).
- Embodiment 3k is the method of Embodiment 3b, wherein the alkyne group comprises monobenzocyclooctyne (MOBO).
- Embodiment 3l is the method of Embodiment 3b, wherein the alkyne group comprises tetramethoxy DIBO (TMDIBO).
- Embodiment 3m is the method of any one of
Embodiments 2 to 3l, wherein the azide group comprises NHS-azide. - Embodiment 4 is the method of
Embodiment 1, wherein one of the first and second click reaction partners comprises an alkene group, and the other click reaction partner comprises a diene. - Embodiment 4a is the method of Embodiment 4, wherein the diene comprises a tetrazine or tetrazole group.
- Embodiment 4b is the method of Embodiment 4 or 4a, wherein the alkene group comprises norbornene.
- Embodiment 4c is the method of Embodiment 4 or 4a, wherein the alkene group comprises trans-cyclooctene (TCO).
- Embodiment 5 is the method of any one of
Embodiments 1 to 4c, wherein the polypeptide is an antibody or an antigen binding fragment thereof. - Embodiment 6 is the method of Embodiment 5, wherein the antibody is a monoclonal antibody, or an antigen binding fragment thereof.
- Embodiment 6a is the method of any one of
Embodiments 1 to 6, wherein the modified polypeptide is obtained by randomly conjugating one or more azide groups to the polypeptide. - Embodiment 6b is the method of any one of
Embodiments 1 to 6, wherein the modified polypeptide is a modified antibody or antigen binding fragment thereof obtained by site specific incorporation of the first click reaction partner. - Embodiment 6c is the method of Embodiment 6b, wherein the modified antibody or antigen binding fragment thereof is obtained by trimming the antibody or antigen binding fragment thereof with a bacterial endoglycosidase specific for the β-1,4 linkage between the core GlcNac residue(s) in the Fc-glycosylation site(s) of the antibody to obtain a trimmed antibody or antigen binding fragment thereof, and reacting the trimmed antibody or antigen binding fragment thereof with an azide sugar, preferably UDP-GalNaz azido sugar substrate, in the presence of a sugar transferase, preferably GalT galactosyltransferase.
- Embodiment 6d is the method of Embodiment 6b, wherein the modified antibody or antigen binding fragment thereof is obtained by deglycosylating the antibody or antigen binding fragment thereof with an amidase to obtain a deglycosylated antibody or antigen binding fragment thereof, and reacting the deglycosylated antibody or antigen binding fragment thereof with an azido amine, preferably 3-azido propylamine, in the presence of a microbial transglutaminase.
- Embodiment 6e is the method of any one of Embodiments 6 to 6d, wherein the antibody is an antibody that binds to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8.
- Embodiment 6f is the method of Embodiment 6e, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 7 is the method of any one of
Embodiments 1 to 6d, wherein the radiometal ion is 32P, 47Sc, 67Cu, 77As, 89Sr, 90Y, 99Tc, 105Rh, 109Pd, 111Ag, 131I, 153Sm, 159Gd, 165Dy, 166Ho, 169Er, 177Lu, 186Re, 188Re, 194Ir, 198Au, 199Au, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 255Fm, 227Th, 62Cu, 64Cu, 67Ga, 68Ga, 86Y, 89Zr, or 111In. - Embodiment 7a is the method of any one of
Embodiments 1 to 6d, wherein the radiometal ion is 225Ac. - Embodiment 7b is the method of any one of
Embodiments 1 to 6d, wherein the radiometal ion is 111In. - Embodiment 7c is the method of any one of
Embodiments 1 to 6d, wherein the radiometal ion is 89Zr. - Embodiment 8 is the method of any one of
Embodiments 1 to 7c, wherein the chelating moiety is covalently linked to the second click reaction partner via a linker. - Embodiment 9 is the method of any one of
Embodiments 1 to 8, further comprising reacting an electrophile on a side chain, preferably the amino side chain of a lysine on or introduced to the polypeptide, with a sulfhydryl group covalently linked to the first click reaction partner to obtain the modified polypeptide, preferably NHS-azide. -
Embodiment 10 is a method of any one ofEmbodiments 1 to 9, wherein the modified polypeptide comprises the polypeptide covalently linked, directly or via a linker, to an azide, tetrazine or tetrazole group. - Embodiment 11 is the method of any one of Embodiments 1 to 10, wherein the chelant comprises a macrocycle, preferably a structure of formula (I):
- wherein each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
-
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl; and
- Z is (CH2)nY, wherein
- n is 1-10, and
- Y is an electrophilic or nucleophilic moiety covalently linked to the second click reaction partner;
- alternatively, Z is hydrogen; and
- each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl, or an electrophilic or nucleophilic moiety covalently linked to the second click reaction partner.
- Embodiment 12 is the method of any one of Embodiments 1 to 11, wherein the chelating moiety comprises the structure of formula (II):
- Embodiment 12a is the method of any one of Embodiments 1 to 11, wherein the chelating moiety comprises a chelant having an open chain ligand, preferably the chelating moiety having a structure of formula (III):
- Embodiment 12b is the method of any one of
Embodiments 1 to 10, wherein the chelating moiety comprises a chelant selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA), deferoxamine (DFO), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N″,N′″,N″″,N′″″-hexaacetic acid (HEHA), 1,4,7,10,13-pentaazacyclopentanadecane-N,N′,N″,N′″, N″″-pentaacetic acid (PEPA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) Macropa (Thiele et al., An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017 Nov. 13; 56(46): p. 14712-14717), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrapropionic acid (DOTPA), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid (TETPA), and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP). - Embodiment 12c is the method of Embodiment 12b, wherein the chelant comprises 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA).
- Embodiment 12d is the method of Embodiment 12b, wherein the chelant comprises deferoxamine (DFO).
-
Embodiment 13 is a method of labeling a polypeptide, preferably an antibody or an antigen binding fragment thereof, with a radiometal ion, preferably 225Ac, 111In or 89Zr, the method comprising: -
- a. providing a modified polypeptide, preferably a modified antibody or antigen binding fragment thereof comprising the polypeptide or antibody or antigen binding fragment thereof covalently linked to an azide, tetrazine or tetrazole group;
- b. providing a radiocomplex comprising the radiometal ion, preferably 225Ac, 111In or 89Zr, associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to an alkyne or an alkene group; and
- c. contacting the modified polypeptide or antibody or antigen binding fragment thereof with the radiocomplex under a condition to allow the azide, tetrazine or tetrazole group to react with the alkyne or the alkene group to thereby label the polypeptide or antibody or antigen binding fragment thereof with the radiometal ion, preferably 225Ac, 111In or 89Zr, wherein the chelant comprises a structure of formula (I):
- wherein each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl; and
- Z is (CH2)nY, wherein
-
- n is 1-10, and
- Y is an electrophilic or nucleophilic moiety covalently linked to the alkyne group; alternatively, Z is hydrogen; and
- each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl, or an electrophilic or nucleophilic moiety covalently linked to the alkyne group.
- Embodiment 13a is the method of
Embodiment 13, wherein the chelant comprises 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA). - Embodiment 13b is the method of Embodiment 13, wherein the chelating moiety comprises the structure of formula (II):
- Embodiment 13d is a method of labeling a polypeptide, preferably an antibody or an antigen binding fragment thereof, with a radiometal ion, preferably 225Ac, 111In or 89Zr, the method comprising:
-
- a. providing a modified polypeptide, preferably a modified antibody or antigen binding fragment thereof comprising the polypeptide or antibody or antigen binding fragment thereof covalently linked to an azide, tetrazine or tetrazole group;
- b. providing a radiocomplex comprising the radiometal ion, preferably 225Ac, 111In or 89Zr, associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to an alkyne or an alkene group; and
- c. contacting the modified polypeptide or antibody or antigen binding fragment thereof with the radiocomplex under a condition to allow the azide, tetrazine or tetrazole group to react with the alkyne or the alkene group to thereby label the polypeptide or antibody or antigen binding fragment thereof with the radiometal ion, preferably 225Ac, 111In or 89Zr, wherein the chelant comprises an open chain ligand, preferably deferoxamine (DFO).
- Embodiment 14 is the method of any one of
Embodiments 13 to 13c, wherein the chelant is covalently linked to the alkyne or an alkene group via a linker. - Embodiment 15 is the method of any one of
Embodiments 13 to 14, further comprising reacting an electrophile on a side chain, preferably the amino side chain of a lysine on or introduced to the polypeptide, preferably the antibody or antigen binding fragment thereof, with a sulfhydryl group covalently linked to the azide, preferably NHS-azide, to obtain the modified polypeptide or antibody or antigen binding fragment thereof. - Embodiment 16 is the method of any one of
Embodiments 13 to 15, wherein the polypeptide, preferably antibody or antigen binding fragment thereof, is covalently linked to the azide via a linker. - Embodiment 17 is the method of Embodiment 13, wherein the polypeptide is an antibody or antigen binding fragment thereof, the radiometal ion is 225Ac, 111In or 89Zr, and the chelating moiety comprises the structure of formula (II):
- Embodiment 17a is the method of Embodiment 13c, wherein the polypeptide is an antibody or antigen binding fragment thereof, the radiometal ion is 225Ac, 111In or 89Zr, and the chelating moiety comprises the structure of formula (III):
- Embodiment 17 is the method of any one of
Embodiments 13 to 17a, wherein the polypeptide is an antibody that binds to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8. - Embodiment 17c is the method of Embodiment 17b, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 18 is a method of dually labeling a polypeptide with two radiometal ions, the method comprising:
-
- a. providing a modified polypeptide comprising the polypeptide covalently linked to a first click reaction partner and a second click reaction partner;
- b. providing a first radiocomplex comprising the first radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a third click reaction partner; and
- c. providing a second radiocomplex comprising the second radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a fourth click reaction partner; and
- d. contacting the modified polypeptide with the first and second radiocomplexes under a condition to allow the first click reaction partner to react with the third click reaction partner, and the second click reaction partner to react with the fourth click reaction partner, to thereby label the polypeptide with the first and second radiometal ions.
- Embodiment 19 is the method of Embodiment 18, wherein one of the first and second click reaction partners comprises an alkyne group, and the other of the first and second click reaction partner comprises an azide, and wherein one of the third and fourth click reaction partners comprises an alkene group, and the other of the third and fourth click reaction partner comprises a diene.
-
Embodiment 20 is the method of Embodiment 18 or 19, wherein the first or second radiometal ion is a diagnostic emitter, and the other is a therapeutic emitter. - Embodiment 21 is the method of Embodiment 18 or 19, wherein both the first and second radiometal ions are therapeutic emitters.
- Embodiment 21a is the method of
Embodiment 20 or 21, wherein the diagnostic emitter is 62Cu, 64Cu, 67Ga, 68Ga, 86Y, 89Zr, or 111In. - Embodiment 21b is the method of any one of
Embodiments 20 to 21a, wherein the therapeutic emitter is 32P, 47Sc, 67Cu, 77As, 89Sr, 90Y, 99Tc, 105Rh, 109Pd, 111Ag, 131I, 153Sm, 159Gd, 165Dy, 166Ho, 169Er, 177Lu, 186Re, 188Re, 194Ir, 198Au, 199Au, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 255Fm or 227Th. - Embodiment 22 is a pharmaceutical composition comprising a radiolabeled polypeptide prepared by a method of any one of
Embodiments 1 to 21b and a pharmaceutically acceptable carrier. - Embodiment 23 is a method of treating or diagnosing a disease or disorder, particularly a neoplastic disease or disorder, in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of Embodiment 22.
- Embodiment 24 is the method of Embodiment 23, wherein the pharmaceutical composition comprises two compositions to be administered sequentially, the first comprising the modified polypeptide, and the second comprising the radiocomplex or radiocomplexes.
-
Embodiment 25 is a theranostic agent comprising a radiolabeled antibody prepared by a method of any one ofEmbodiments 1 to 21b and a pharmaceutically acceptable carrier, wherein the immunological properties of the radiolabeled antibody are preserved. - Embodiment 26 is the theranostic agent of
Embodiment 25, wherein the radiometal ion is a diagnostic emitter, preferably 89Zr. - Embodiment 27 is the theranostic agent of
Embodiment 25, wherein the radiometal ion is a therapeutic emitter, preferably 225Ac. - Embodiment 27a is the theranostic agent of
Embodiment 25, wherein the radiometal ion is 111In. - Embodiment 27b is the theranostic agent of any one of
Embodiments 25 to 27a, wherein the polypeptide is antibody that binds to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8. - Embodiment 27c is the theranostic agent of Embodiment 27b, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 27d is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (IV):
-
- formula (IV) (DOTA-Ac-DBCO-protein), alternatively, the 225Ac is substituted with another radiometal ion, such as 32P, 47Sc, 67Cu, 77As, 89Sr, 90Y, 99Tc, 105Rh, 109Pd, 111Ag, 131I, 153Sm, 159Gd, 165Dy, 166Ho, 169Er, 177Lu, 186Re, 188Re, 194Ir, 198Au, 199Au, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 255Fm, 227Th, 62Cu, 64Cu, 67Ga, 68Ga, 86Y, 89Zr, or 111In.
- Embodiment 27e is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (V):
- formula (V) (DOTA-In-DBCO-protein).
- Embodiment 27f is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (VI):
-
- formula (VI) (DFO-Zr-DBCO-protein), alternatively, the 89Zr is substituted with another radiometal ion, such as 32P, 47Sc, 67Cu, 77As, 89Sr, 90Y, 99Tc, 105Rh, 109Pd, 111Ag, 131I, 153Sm, 159Gd, 165Dy, 166Ho, 169Er, 177Lu, 186Re, 188Re, 194Ir, 198Au, 199Au, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 255Fm, 227Th, 62Cu, 64Cu, 67Ga, 68Ga, 86Y, or 111In.
- Embodiment 27g is the theranostic agent of any one of Embodiments 25 to 27c, wherein the radiolabeled antibody has the formula of formula (VII):
- formula (VII) (DOTA-Zr-DBCO-protein).
- Embodiment 27h is the theranostic agent of any one of
Embodiments 25 to 27g, wherein the radiolabeled antibody has a chelator:antibody ratio (CAR) of less than 3. - Embodiment 27i is the theranostic agent of any one of
Embodiments 25 to 27h, wherein the radiolabeled antibody has a chelator:antibody ratio (CAR) of 2. - Embodiment 28 is a combination, preferably a kit, comprising:
-
- a. a modified polypeptide comprising a polypeptide covalently linked to a first click reaction partner; and
- b. a radiocomplex comprising a radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner;
- wherein the combination is to be used for labeling the polypeptide with the radiometal ion.
- Embodiment 28a is the combination or kit of Embodiment 28, wherein the chelant comprises a macrocycle.
- Embodiment 28b is the combination or kit of Embodiment 28, wherein the chelant comprises an open chain ligand.
- Embodiment 29 is the combination or kit of Embodiment 28, which is to be used for labeling the polypeptide with the radiometal ion via a reaction between the first and second click reaction partners in vitro.
-
Embodiment 30 is the combination or kit of Embodiment 28, which is to be used for labeling the polypeptide with the radiometal ion via a reaction between the first and second click reaction partners in vivo. - Embodiment 31 is a composition comprising a modified polypeptide comprising a polypeptide covalently linked to a first click reaction partner.
- Embodiment 32 is a composition comprising a radiocomplex comprising a radiometal ion associated with a chelating moiety, wherein the chelating moiety comprises a chelant covalently linked to a second click reaction partner.
- Embodiment 32a is the composition of Embodiment 32, wherein the chelant comprises a macrocycle.
- Embodiment 32b is the composition of Embodiment 32, wherein the chelant comprises an open chain ligand.
- Embodiment 33 is the combination or kit of any one of Embodiments 28 to 30 or the composition of Embodiment 31 or 32, wherein the polypeptide is an antibody or an antigen binding fragment thereof.
- Embodiment 33a is the combination or kit or the composition of Embodiment 33, wherein the antibody is capable of binding to human prostate-specific membrane antigen (PSMA) or an antigen binding fragment thereof, preferably the antibody comprises a HC CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8.
- Embodiment 33b is the combination or kit or the composition of Embodiment 33a, wherein the antibody comprises a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10.
- Embodiment 33c is the combination or kit or the composition of Embodiment 33a or 33b, wherein the antibody or antigen binding fragment thereof is covalently linked to an azide group.
- Embodiment 33d is the combination or kit or the composition of Embodiment 33c, wherein the antibody or antigen binding fragment thereof is covalently linked to the azide group randomly.
- Embodiment 33e is the combination or kit or the composition of Embodiment 33c, wherein the antibody or antigen binding fragment thereof is covalently linked to the azide group site specifically.
- Embodiment 33f is the combination or kit or the composition of Embodiment 33e, wherein the antibody or antigen binding fragment thereof is covalently linked to the azide group via a method comprising: trimming the antibody or antigen binding fragment thereof with a bacterial endoglycosidase specific for the β-1,4 linkage between the core GlcNac residue(s) in the Fc-glycosylation site(s) of the antibody to obtain a trimmed antibody or antigen binding fragment thereof, and reacting the trimmed antibody or antigen binding fragment thereof with an azide sugar, preferably UDP-GalNaz azido sugar substrate, in the presence of a sugar transferase, preferably GalT galactosyltransferase.
- Embodiment 33g is the combination or kit or the composition of Embodiment 33e, wherein the modified antibody or antigen binding fragment thereof is obtained by a method comprising deglycosylating the antibody or antigen binding fragment thereof with an amidase to obtain a deglycosylated antibody or antigen binding fragment thereof, and reacting the deglycosylated antibody or antigen binding fragment thereof with an azido amine, preferably 3-azido propylamine, in the presence of a microbial transglutaminase.
- Embodiment 34 is the combination, kit or composition of any one of Embodiments 33 to 33g, wherein the radiometal ion comprises 225Ac, 111In or 89Zr.
- Embodiment 35 is the combination, kit or composition of Embodiment 34, wherein the chelant comprises a macrocycle, preferably a structure of formula (I):
- wherein each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
-
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl; and
- Z is (CH2)nY, wherein
- n is 1-10, and
- Y is an electrophilic or nucleophilic moiety covalently linked to the alkyne group; alternatively, Z is hydrogen; and
- each of R1, R2, R3 and R4 is independently CHQCO2X, wherein
- Q is independently hydrogen, C1-C4 alkyl or (C1-C2 alkyl) phenyl, and
- X is independently hydrogen, benzyl, C1-C4 alkyl, or an electrophilic or nucleophilic moiety covalently linked to the alkyne group.
- Embodiment 36 is the combination, kit or composition of Embodiment 35, wherein the electrophilic or nucleophilic moiety is covalently linked to the alkyne group via a linker.
- Embodiment 37 is the combination, kit or composition of Embodiment 35 or 36, wherein the chelating moiety comprises a structure of formula (II):
- Embodiment 37a is the combination, kit or composition of Embodiment 34, wherein the chelating moiety comprises a chelant having an open chain ligand, preferably the chelating moiety comprises a structure of formula (III):
- Embodiment 38 is the combination, kit or composition of any one of Embodiments 34 to 37, wherein the polypeptide is covalently linked to the azide via a linker.
- Embodiment 39 is a method of treating or diagnosing a disease or disorder, particularly a neoplastic disease or disorder, in a subject in need thereof, comprising administering to the subject the theranostic agent of any one of Embodiments 25-27d, or the combination of anyone of Embodiments 28 and 33 to 38.
-
Embodiment 40 is a method of treating or diagnosing a disease or disorder, particularly a neoplastic disease or disorder, in a subject in need thereof, comprising administering to the subject the composition of Embodiment 31 and the composition of Embodiment 32, preferably the polypeptide is an antibody. - The following examples of the invention are to further illustrate the nature of the invention. It should be understood that the following examples do not limit the invention and that the scope of the invention is to be determined by the appended claims.
- Monoclonal Antibodies (mAbs):
- A human IgG4 antibody that binds to human prostate-specific membrane antigen (PSMA), referred to herein as “anti-PSMA mAb” with designation “PSMB127”, has a heavy chain (HC) CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8, and has a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10. Anti-PSMA mAb was expressed and purified using standard chromatography methods.
- A human IgG4 S228P/F234A/L235A (IgG4-PAA) antibody isotype control for the anti-PMSA mAb, referred to herein as “control mAb”, has a HC sequence of SEQ ID NO: 1 and a LC sequence of SEQ ID NO: 2. The commercial antibodies trastuzumab (Herceptin), cetuximab (Erbitux), pertuzumab (Perjeta), and panitumumab (Vectibix) were purchased from Roche, Lilly, Roche, and Amgen respectively. Mouse anti-human Her2 mAb was obtained from BioXCell (catalog #BE0277). Trastuzumab, pertuzumab, and anti-human Her2 mAb bind to human Her2. Cetuximab and panitumumab bind to human EGFR.
- Conjugation:
- A stock solution of the antibody (1-10 mg/mL) in 10 mM sodium acetate pH 5.2, phosphate-buffered saline pH 7, or other compatible buffer was mixed with 20% (v/v) of 1 M sodium carbonate buffer pH 9 to a final pH of ˜9. NHS-PEG4-azide (Thermo catalog #26130) was dissolved in DMSO to a final concentration of 100 mM, and 0.2% (v/v) of the stock was added to produce a molar excess of ˜3-10 relative to the mAb. The reaction was incubated at 22° C. for 10 minutes followed by quenching with the addition of 1 M Tris pH 7.5 to a final concentration of 50 mM Tris.
- Purification:
- The azide-mAb conjugate was purified and exchanged into a compatible buffer (PBS; 20
mM HEPES 150 mM, NaCl pH 7.5; or 10 mM sodium acetate pH 5.2) using a method such as Zeba desalting columns with 7K MW cutoff (Thermo), dialysis; standard protein A affinity chromatography; or another compatible method. After purification, the conjugate was concentrated to 10-20 mg/mL using Amicon concentrators with 50K MW cutoff (Millipore). - LC/MS Analysis:
- The chelator:antibody ratio (CAR) was determined by LC/MS analysis with an Agilent G6224 MS-TOF instrument equipped with an Agilent PLRP-S column (300-Angstrom, 2.1×150 mm; catalog #PL1912-3301) (Table 1). The mass spectrum was deconvoluted using the maximum entropy algorithm over the m/z range 2000-3200 for the masses 140-170 kDa.
- Analytical Size-Exclusion Chromatography (SEC):
- Analytical SEC was performed to determine the oligomeric state of the antibodies and antibody conjugates and ensure that the conjugation process had not led to aggregation. An Agilent 1200 series HPLC equipped with a Tosoh TSKgel G3000SWxl (Tosoh Bioscience #08541) 7.8 mm×30 cm column was used;
mobile phase 1×PBS; flow rate 0.8 ml/ml; injection volume 15 μL; protein concentration 0.1-2 mg/mL. -
TABLE 1 Conjugation efficiency Antibody Isotype CAR anti-PSMA mAb Human IgG4 2.4 control mAb Human IgG4 2.0 Trastuzumab Humanized IgG1 2.5 Cetuximab Chimeric 3.6 human/mouse IgG1 Pertuzumab Humanized IgG1 2.3 Panitumumab Human IgG2 3.0 Anti-human Her2 Mouse IgG2a 3.1 - Non-Antibody Polypeptides:
- Transferrin, human holo-Transferrin was purchased from R&D Systems (catalog #2914-HT) and dissolved in water to 10 mg/mL. EGF, human epidermal growth factor (EGF) was purchased from Sino Biological (catalog #10605-HNAE).
- Conjugation:
- A stock solution of the polypeptides (1-10 mg/mL) in 10 mM sodium acetate pH 5.2, phosphate-buffered saline pH 7, or other compatible buffer, was mixed with 20% (v/v) of 1 M sodium carbonate buffer pH 9 to a final pH of ˜9. NHS-PEG4-azide (Thermo catalog #26130) was dissolved in DMSO to a final concentration of 100 mM, and 0.2% (v/v) of the stock was added to produce a molar excess of ˜3-10 relative to the protein. The reaction was incubated at 22° C. for 10 minutes followed by quenching with 1 M Tris pH 7.5 to a final concentration of 50 mM. The conjugation efficiency is shown in Table 2.
-
TABLE 2 Conjugation Efficiency Protein Chelator:protein ratio Transferrin 3.6 EGF 1.1 - Antibody glycans were trimmed with GlycINATOR (Genovis), a bacterial endoglycosidase specific for the β-1,4 linkage between the core GlcNac residues in the Fc-glycosylation site(s) leaving the inner most GlcNAc intact on the Fc, which can then be used for site-specific incorporation of azido sugars. More specifically, immobilized GlycINATOR on agarose beads packed into a column (Genovis) was equilibrated in Tris-buffered saline pH 7.4 (TBS). 1 mL of mAb at 5-10 mg/mL was added to the resin and incubated on a rocker for 1 hour at RT. mAb was eluted by spinning at 100×g for 1 minute. The column was eluted 3 more times with 0.5 mL TBS. The elutions containing trimmed mAb were pooled, and the supplied buffer additive (Genovis) was added along with UDP-GalNaz azido sugar substrate and GalT galactosyltransferase enzyme. The reaction was incubated overnight at 30° C. The final azido mAb was purified using a mAb Select column (GE) on an AKTA Avant instrument. Azide modification was confirmed by LC-MS with the CAR determined to be exactly 2.
- Azido groups were installed site-specifically on the antibody at positions Gln295 essentially as described (Dennler et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconj Chem 2014 Mar. 19; 25(3): p. 569-78). Anti-PSMA mAb was deglycosylated with Rapid PNGase F (New England Biolabs), an amidase which cleaves between the innermost GlcNAc and asparagine residues of high mannose, hybrid, and complex oligosaccharides and allows for complete deglycosylation and release of all N-glycans, including N-glycans from both conserved (e.g., Fc Asn297) and non-conserved (e.g., Fab N-glycans) glycosylation sites. 10 mL of antibody at 1 mg/mL in sodium acetate buffer pH 5.2 was incubated with 5 μL of PNGase F overnight at 37° C., and deglycosylation was confirmed by LC-MS. PNGase F was removed by 4 cycles of concentration and dilution with an Amicon device (50 kDa cutoff). For conjugation of 3-azido propylamine (3-APA; Click Chemistry Tools), the deglycosylated mAb (0.5-1 mg/mL) was brought to pH 7-7.5 by addition of 2% (v/v) of 0.5 M HEPES pH 7.5. 100 equivalents of 3-APA were added along with 5-10% w/v of Activa TI transglutaminase (Ajinomoto), an MTG. The reaction was incubated at 37° C. for 1-4 hours followed by purification of the azide-modified mAb on a mAbSelect Sure column using standard chromatographic methods. The conjugate was characterized by LC-MS and the CAR was determined to be 2.
- Synthesis of 22Ac-DOTA-GA-DBCO:
- 22Ac(NO3)3 was purchased from Oak Ridge National Laboratory. 1,4,7,10-tetraazacyclododececane, 1-(glutaric acid)-4,7,10-triacetic acid-(3-amino-propanoic acid)dibenzocyclo-octyne (DOTA-GA-DBCO) was custom synthesized. The synthesis was based on Bernhard et al. Chem. Eur. J. 2012, 18, 7834-7841. DBCO-amine (3-Amino-1-[(5-aza-3,4:7,8-dibenzocyclooct-1-yne)-5-yl]-1-propanone, Sigma) was reacted with the DOTA-GA anhydride and the product was purified by reverse-phase HPLC.
- Quantification of Actinium-225 was achieved using a Capintec CRC-55TW dose calibrator whereby 225Ac(NO3)3 dissolved in 0.1 N HCl to make a 10 mCi/mL solution. To a solution of tetramethylammonium acetate (1 M solution, 7.5 μL, 7.5 μmol), DOTA-GA-DBCO (1 mg/mL in water, 2.5 μL, 3.4 nmol) and NaOH (0.1 N, 2.5 μL, 0.25 μmol) in a plastic vial was added to 225Ac(NO3)3 (10 mCi/mL in 0.1 N HCl, 5 μL, 50 μCi, 0.0038 nmol). The pH of the mixture was observed to be ˜6.5 by pH paper. The vial was placed on a shake block at 80° C. and 290 rpm for 30 min., and the vial was allowed to cool to room temperature.
- Synthesis of 111In-DOTA-GA-DBCO:
- 111InCl3 in 0.05 M HCl was purchased from GE Healthcare. To a solution of tetramethylammonium acetate (1 M solution, 7.5 μL, 7.5 μmol), DOTA-GA-DBCO (1 mg/mL in water, 2.5 μL, 3.4 nmol) and HCl (0.1 N, 5 μL) in a plastic vial was added 111InCl3 in 0.05 N HCl (5 μL, 104.3 μCi measured in a Capintec CRC-55TW dose calibrator, 0.0022 nmol). The pH of the mixture was observed to be ˜5.5 by pH paper. The vial was placed on a shake block at 60° C. and 290 rpm for 30 min., and the vial was allowed to cool to room temperature.
- Synthesis of 89Zr-DFO-DBCO:
- 89Zr oxalate was purchased from 3D Imaging. DFO-DBCO was purchased from Macrocyclics (Plano, Tex. catalog #B-773), dissolved in DMSO to 0.5 mg/mL, and diluted in water to 25 μg/mL.
- 2 mCi of Zr-89 was transferred to a metal-free micro-centrifuge tube, and 1 M oxalic acid was added to reach a total volume of 80 μL. 12 μL of 2 M potassium carbonate was added in 2 μL increments, and the mixture stirred with a pipet tip until bubbling stopped. 120 μL of 1 M HEPES was then added followed by 300 μL of water. The pH of the solution was tested, and additional 2 M potassium carbonate was added to raise the pH to 6-6.5 if necessary. 136 μL of the DFO-DBCO stock (3.4 μg) was added, and the reaction was incubated for 1 hour at RT. The chelate was analyzed by spotting 0.5 μL of the reaction on a TLC Green strip (Biodex) and eluting with 20% NaCl. After elution, the strip was scanned with a PerkinElmer Cyclone Plus phosphor imager to ensure that the majority of the Zr-89 remained at the baseline, indicating chelation by DFO-DBCO.
- Synthesis of 89Zr-DOTA-GA-DBCO:
- To a Waters Sep-pak Light QMA strong anion exchange cartridge (acrylic acid/acrylamide copolymer on Diol silica, Surface functionality: C(O)NH(CH2)3N(CH3)3 +Cl−, 300 Å pore size, 37-55 m particle size, 230 eq/gram ion exchange capacity), MeCN (6 mL) was added followed by 0.9% saline (10 mL) then water (10 mL). A solution of 89Zr(ox)2 in 1.0 M oxalic acid (2 μL, 290 μCi) was added to the pre-conditioned cartridge. The cartridge was in turn washed with de-ionized water (20 ml) to remove excess oxalic acid followed by elution of 89ZrCl4 off the column with 1.0 M HCl(aq.) (100 μL each) to afford a total volume of 400 μL with recovery of 248 μCi (86%), the majority of activity being in fraction 3. The combined aliquots were then evaporated to dryness.
- 10 μL of DOTA-GA-DBCO (1.0 mg/mL in metal free water, 10 μg, 13.6 nmol) was added to the 89ZrCl4 (268 uCi, 50 μL). The solution of DOTA-GA-DBCO/89Zr was diluted in 150 μL of 1.0 M HEPES. The pH of the mixture was adjusted to pH 7.5 (Pandya et al., Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci. 2017 Mar. 1; 8(3): p. 2309-2314). The solution was then incubated at 90° C. for 60 min. The yield of 89Zr-DOTA-GA-DBCO complex was determined to be 98% by SPC25 column (Sigma Aldrich part number SPC25120-50G) eluted with 1% NH4OH solution. Un-chelated 89Zr stays on the column, while 89Zr-DOTA-GA-DBCO complex is eluted out.
- See
FIGS. 1 and 2 for schematics of schematics of radiolabeling antibodies according to methods of the invention. - Synthesis of Anti-PSMA mAb-Dibenzo-[1,2,3]-Triazoloazocine-GA-DOTA-225Ac (site specific, CAR=2):
- Random or site-specific azide-modified antibody (site-specific, CAR=2 or random, average CAR between 1 and 4) in PBS or other compatible buffer (10-20 mg/mL) was added to the solution of 225Ac-DOTA-GA-DBCO produced as described. The final pH of the mixture was ˜6.5 by pH paper. The reaction solution was gently agitated and allowed to stand still at room temperature for 3 h before purification with a PD-10 column (GE Healthcare) pre-conditioned with 15 mL of NaOAc buffer, 10 mM, pH 6-6.5 or another compatible buffer. The reaction mixture was pipetted into the reservoir of the pre-conditioned PD-10 column, and the eluate was collected in plastic tubes. The reaction vial was washed with NaOAc buffer (0.2 mL×3), the washings were pipetted into the reservoir of the PD-10 column, and the eluate was collected. NaOAc buffer was continuously applied into the reservoir of the PD-10 column, and the eluate was collected in plastic tubes with each tube collecting ˜1 mL of the eluate, until a total of 10 mL of eluate was collected.
- The purity of each fraction collected was assessed by iTLC-SG (Agilent) using citrate-H2O-MeOH solution as the mobile phase. Pure fraction(s) were combined to afford final product in 10 mM NaOAc buffer. The product solution was analyzed by HPLC for chemical and radiochemical purity. The antibody concentration in the product solution was determined by UV absorption using a standard curve. The activity of the product solution was in turn quantified using a Capintec CRC-55TW dose calibrator.
- Quality Control of Ac-225 Chelation:
- A chelation challenge was employed using diethylenetriaminepentaacetic acid (DTPA) as a quality control for a purified product. A 10 mM aqueous solution of Na5DTPA was added to a sample solution containing 225Ac labeled mAb until the [DTPA]/[mAb]=500-1,000. A 50 mM aqueous solution of Na5DTPA was added to an aliquot of the purified product in solution containing 225Ac labeled mAb until the [DTPA]/[mAb]=50,000-100,000. The two mixtures were placed on a shake block at room temperature and 290 rpm for 30 min. The mixture was spotted on iTLC-SG and developed with citrate-H2O-MeOH solution as the mobile phase. Under these conditions, free 225Ac migrates to the solvent front and the bound 225Ac-mAb stays at the baseline.
- Synthesis of Anti-PSMA mAb-Dibenzo-[1,2,3]-Triazoloazocine-GA-DOTA-111In:
- Random or site-specific azide-modified anti-PSMA mAb in 10 mM NaOAc (site-specific, CAR=2 or random, average CAR between 1 and 4) was added to the solution of 111In-DOTA-GA-DBCO produced as described. The reaction solution was gently agitated and allowed to stand still at room temperature for 2 h before passing through a PD-10 column. The PD-10 column was pre-conditioned by passing 15 mL of NaOAc buffer, 10 mM, pH 6-6.5, through the column, and the washings were discarded. The reaction mixture was then pipetted into the reservoir of the pre-conditioned PD-10 column, and the eluate was collected in plastic tubes. The reaction vial was washed with NaOAc buffer (0.2 mL×3), the washings were pipetted into the reservoir of the PD-10 column, and the eluate was collected. NaOAc buffer was continuously applied into the reservoir of the PD-10 column, and the eluate was collected in plastic tubes with each tube collecting ˜1 mL of the eluate, until a total of 10 mL of eluate was collected.
- The purity of each fraction collected was assessed by iTLC-SG using 10 mM EDTA aqueous solution (pH=5-6) as the mobile phase. Pure fraction(s) were combined to afford final product in 10 mM NaOAc buffer. The product solution was analyzed by HPLC for chemical and radiochemical purity. The antibody concentration in the product solution was determined by UV absorption using a standard curve. The activity of the product solution was in turn quantified using a Capintec CRC-55TW dose calibrator.
- Quality Control of In-111 Chelation:
- A chelation challenge was employed using DTPA as a quality control for a purified product: A 10 mM aqueous solution of Na5DTPA was added to a sample solution containing 111In labeled mAb until the [DTPA]/[mAb]=1000-10,000. The mixture was placed on a shake block at room temperature and 290 rpm for 30 min. The mixture was spotted on iTLC-SG and developed with 10 mM EDTA aqueous solution (pH=5-6) as the mobile phase. Free 111In or loosely bound 111In migrates to the solvent front and the tightly bound 111In-mAb stays at the baseline.
- Synthesis of Anti-PSMA mAb-Dibenzo-[1,2,3]-Triazoloazocine-DFO-Zr-89
- 800 μg of random azide-modified anti-PSMA mAb (average CAR between 1 and 4; the same procedure can be carried out with a site-specific azido-mAb) in 10 mM HEPES 50 mM NaCl pH 7.5 or other compatible buffer was added to the solution of 89Zr-DFO-DBCO produced as described and incubated at 37° C. for 1.5 hrs before passing through a PD-10 column. The PD-10 column was pre-conditioned by passing 15 mL of isotonic saline through the column, and the washings were discarded. The reaction mixture was then pipetted into the reservoir of the pre-conditioned PD-10 column, and the eluate was collected in plastic tubes. Saline was continuously applied into the reservoir of the PD-10 column, and the eluate was collected in plastic tubes with each tube collecting 0.5 mL of the eluate, until a total of 10 mL of eluate was collected. Activity of each fraction and of the material remaining on the column was determined with a dose calibrator. The product peak, usually fractions 4-7 was pooled to afford the final product. The product solution was analyzed by HPLC for chemical and radiochemical purity. The antibody concentration in the product solution was determined by UV absorption using a standard curve. The activity of the product solution was quantified using a dose calibrator.
- Synthesis of Anti-PMSA mAb-DOTA-89Zr
- Azide-modified anti-PSMA mAb conjugate (CAR=1-4), modified by random azide conjugation, in 20 mM HEPES 50 mM NaCl pH 7.5 (10.1 mg/mL, 200 μL, ˜13.5 nmol) was added to the solution of 89Zr-DOTA-GA-DBCO produced, as described above. The final pH of the mixture was adjusted to 7.0. The reaction solution was incubated at 37° C. for 2 h, followed by purification on a PD-10 column (GE Healthcare) with either 0.9% saline, a HEPES buffer, or PBS to give the product 89Zr-DOTA-mAb in 64%.
- Quality Control of Zr-89 Chelation:
- For Zr-DFO-mAbs, purified products were analyzed by HPLC only. These conjugates did not retain Zr-89 upon challenge with DTPA or EDTA. Zr-DOTA-mAbs were challenged with the addition of EDTA to 33 mM and incubated overnight at RT. Conjugates were analyzed after challenge by running over a PD-10 column and found to retain 80% of the radioactivity.
- Determining Radiochemical Conversion
- Radiochemical conversion (% RA conversion; see Tables 3-5) was determined by iTLC-SG (Instant Thin Layer Chromatography (iTLC) using a binderless, glass microfiber chromatography paper impregnated with a silica gel (SG)). % RA conversion values are calculated by dividing the integrated value of the product peak's radio signal (of different retention time of radioactive starting material and byproducts) by the value obtained when integrating all radio signal peaks present between the baseline and solvent front. This fraction of product is then expressed as a percentage conversion.
- For Ac-225 incorporated products, sample solutions containing ˜0.1-1 μCi of 22Ac were spotted on the baseline of an iTLC-SG strip approximately 2 cm from the bottom edge. The iTLC-SG strip was developed using a citrate-water-methanol mobile phase (20 mL 0.4 M trisodium citrate/3 mL 2 N HCl/2.3 mL MeOH), allowed to dry at room temperature, and stored for a minimum of 6 h before analysis (reaching secular equilibrium of 225Ac and all daughter nuclides). The iTLC-SG was scanned using a Bioscan AR2000 radio-TLC imaging scanner using a 99mTc setting.
- For In-111 chelates, sample solutions containing ˜0.5-2.5 μCi of 111In were spotted on the baseline of an iTLC-SG strip, approximately 2 cm from the bottom edge. The iTLC-SG strip was developed using 10 mM sodium EDTA pH 5-6 as the mobile phase and then allowed to dry at room temperature. The dried iTLC-SG was scanned using a Bioscan AR2000 radio-TLC imaging scanner using an In-111 setting.
- For Zr-89 chelates the % RA conversion was determined by dividing the activity on the product peak by the total activity including the activity in the PD-10 column, as determined by counting with a dose calibrator.
- Determining Radiochemical Purity of Radiolabeled Proteins
- Radiochemical purity (% RA purity; see Tables 3-4) of Ac-225 and In-111 chelates was determined by SE-HPLC (size exclusion HPLC). For Ac-225, a Tosoh TSKgel column (G3000SWxl7.8 mm×30 cm, 5 um) was used; the column was eluted with DPBS buffer (1×, without calcium and magnesium); flow rate: 0.7 mL/min; 20 min run; room temperature. After HPLC, the eluate was collected in pre-numbered vials with each vial collecting 0.5 min or 1 min of eluate fraction. The eluate-containing vials were left at room temperature for >6 h to allow 225Ac reach the secular equilibrium with its daughter nuclides. The activity in each vial was then counted in a Capintec CRC-55TW well counter. The radio-chromatogram was reconstructed based on the activity in the vials.
- For In-111, Tosoh TSKgel column (G3000SWxl7.8 mm×30 cm, 5 um) was used; the column was eluted with DPBS buffer (lx, without calcium and magnesium); flow rate: 0.7 mL/min; 20 min run; room temperature. Radioactivity detection was accomplished using the above HPLC system and a Perkin Elmer radio flow detector Radiomatic 625TR and equipped with a 0.5 mL flow cell using In-111 setting and Ultima Flo™ M cocktail at a flow rate of 1.4 mL/min.
- For Zr-89 (see Table 5), Tosoh TSKgel column (G3000SWxl7.8 mm×30 cm, 5 um) was used. The column was eluted with citrate-buffered saline; flow rate: 1 mL/min; 20 min run; room temperature. Radioactivity detection was accomplished using the above HPLC system and a Beckman flow through detector coupled to a Bioscan Flow Count instrument.
-
TABLE 3 Actinium-225 radiolabeling of proteins Step 1* Step 2**% RA % RA % RA Spec. Total conversion conversion purity conc. Spec. ac. RA mAb (iTLC) (iTLC) (HPLC) (μCi/mL) (μCi/mg) (μCi) CAR anti-PSMA 88% 73% 80% 17.2 74.9 17.2 3-4 mAb (random azide) anti-PSMA 88% 77% 83% 7.2 102.8 7.2 2 mAb (site specific glycan) anti-PSMA 93% 70% 90% 31.3 74.2 31.3 2.0 mAb (site specific MTG) control mAb 92% 68% 97% 28.1 56.1 28.1 2 (random azide) Panitumumab 87% 65% 95% 24.9 66.6 24.9 3.0 (random azide) Cetuximab 91% 67% 98% 33.7 76.4 33.7 3.6 (random azide) hEGF (random 92% 48% 100% 19.63 1091 19.63 1.1 azide) Transferrin 94% 57% 78% 24.1 83.7 24.1 3.6 (random azide) Trastuzumab 94% 60% 97% 9.88 62.9 9.88 2.5 (random azide) Pertuzumab 94% 63% 92% 16.75 49.9 16.75 2.3 (random azide) Anti-human 85% 78% 94% 21.5 55.0 21.5 3.1 HER2 (random azide) * Step 1 is the chelation of Actinium-225 to DOTA-GA-DBCO** Step 2 is the click reaction the bifunctional chelate to the protein -
TABLE 4 Indium-111 radiolabeling of proteins Step 1* Step 2**% RA % RA % RA Spec. Total conversion conversion purity conc. Spec. ac. RA mAb (iTLC) (iTLC) (HPLC) (μCi/mL) (μCi/mg) (μCi) CAR anti-PSMA 81% 79% 98% 57.6 139.5 72 2.4 mAb (random azide) Transferrin 79% 88% 90% 71.4 410.3 71.4 3.6 (random azide) Panitumumab 46% 79% 99% 82.0 279 82.0 3.0 (random azide) Cetuximab 74% 75% 100% 51.3 290 51.3 3.6 (random azide) * Step 1 is the chelation of Indium-111 to DOTA-GA-DBCO** Step 2 is the click reaction the bifunctional chelate to the protein -
TABLE 5 Zr-89 radiolabeling of anti-PSMA mAb with DFO-DBCO % RA Spec. % RA purity conc. Spec. ac. Total RA mAb conversion (HPLC) (μCi/mL) (μCi/mg) (μCi) CAR anti-PSMA mAb 47% 100% 131 1171 262 2.4 (random azide) - Random and site-specific azido-mAbs (anti-PSMA mAb, Cetuximab, Panitumumab, Trastuzumab, Pertuzumab) at 1-10 mg/mL were mixed with a 5× to 20× excess of unchelated DOTA-GA-DBCO and incubated at RT or 37° C. for 1-24 hours. mAbs were desalted with Zeba desalt spin columns (Thermo) and concentrated with an Amicon centrifuge concentrator (Millipore), rediluted with buffer and concentrated again to remove any remaining DBCO-DOTA. Complete click reaction of all free azides with DBCO-DOTA was confirmed by LC-MS.
- Random and site-specific anti-PSMA mAb azido-mAbs at 1-10 mg/mL were mixed with a 5× to 20× excess of unchelated DOTA-GA-DFO and incubated at RT or 37° C. for 1-24 hours. mAbs were desalted with Zeba desalt spin columns (Thermo) and concentrated with an Amicon centrifuge concentrator (Millipore), rediluted with buffer and concentrated again to remove any remaining DBCO-DFO. Complete click reaction of all free azides with DBCO-DFO was confirmed by LC-MS.
- Cell binding of azide-modified antibodies, DOTA-DBCO-azide modified antibodies, and DFO-DBCO-azide modified antibodies was compared to the parental mAbs for the conjugates described in Table 1. Cell lines expressing the mAb target were treated with antibody or conjugate in a range of a concentrations, and binding was measured by flow cytometry. Panitumumab and Cetuximab conjugates were evaluated for binding to EGFR+A431 cells. Herceptin and Pertuzumab were evaluated for binding to HER2+ SK-BR-3 cells. Anti-PSMA mAb was evaluated for binding to PSMA+C4-2b cells.
- Cell Lines:
- C4-2B cells, a human prostate carcinoma cell line, were obtained from Janssen Oncology (Spring House, Pa.). A431 cells, a human epidermoid carcinoma cell line, and SK-BR-3 cells, a human breast cancer cell line, were obtained from Janssen BioTherapeutics (Spring House, Pa.) with cells originally from ATCC (Manassas, Va.). EGFR Receptor negative MOLM-13 Human Acute Myeloid Leukemia suspension cells were maintained in RPMI1640+25 mM Hepes (Gibco) supplemented with 20% Heat Inactivated Fetal Bovine Serum (Gibco). Cells were grown in RPMI1640+25 mM Hepes (Gibco, Waltham, Mass.) with 10% FBS (Gibco, Waltham, Mass.).
- Flow Cytometry:
- Cells were detached from flask using enzyme free cell dissociation buffer (Gibco, Waltham, Mass.) and strained through a 40 um filter (Falcon). 5×104 cells were seeded per well in a 96-well u-bottom plate. Cells were incubated with conjugated antibody or parental antibody diluted in BSA stain buffer (BD Bioscience, San Jose, Calif.) for 1 hr at 4° C. Cells were washed twice with stain buffer. Cells were then incubated in the dark for 30 min at 4° C. with AlexaFluor647 tagged anti-human IgG secondary antibody (Jackson ImmunoResearch Laboratories). Secondary antibodies were diluted 1:200 in stain buffer containing 3% donkey serum (Rockland Immunochemicals). For the last 10 minutes of the incubation SYTOX™ Green Nucleic Acid Stain (ThermoFisher) was added to cells at a final concentration of 30 nM. Cells were washed twice with stain buffer then resuspended in a final volume of 25 μL/well in stain buffer and read on the iQue Screener flow cytometer (Intellicyt). ForeCyt software was used to analyze data. Live cells were determined by excluding events with high nucleic acid stain. Mean fluorescence intensity (MFI) was determined on live cells and graphed in GraphPad Prism 7 (GraphPad Software) as log of antibody concentration vs. MFI. A non-linear regression curve fit was added to data and EC50 values were calculated.
- For all mAbs and conjugates tested, the parental mAbs and modified mAbs showed similar cell binding (Table 6).
-
TABLE 6 EC50s (nM) of mAbs/conjugates binding to target cells mAb mAb-azide mAb-DOTA mAb-DFO Vectibix 1.3 1.3 0.9 Cetuximab 0.6 0.2 0.4 Herceptin 2.0 0.9 3.1 Pertuzumab 2.5 3.3 4.4 anti-PSMA 5.5 4.7 5.4 4.6 mAb (random azide) anti-PSMA 0.7 0.5 0.7 mAb (glycan) MTG samples mAb Deglycosylated mAb-azide mAb-DOTA mAb-DFO anti- 4.1 3.4 5.0 6.7 4.5 PSMA mAb (MTG) - Cell binding was measured with a radiometric assay using the In-111 radiolabeled proteins described in Table 4. Anti-PSMA mAb and transferrin were tested on C4-2B cells (PSMA+ and transferrin+). Cetuximab and panitumumab were tested on A431 cells (EGFR+) and MOLM-13 cells (EGFR−).
- Adherent cells were detached with Enzyme-Free Cell Dissociation Buffer (Gibco). Detached adherent cells and collected suspension cells were counted and washed with cold Stain Buffer (BD Biosciences). Varying numbers of cells in 200 μL Stain Buffer were added to microcentrifuge tubes and placed on ice. 0.5 μCi of In-111 labeled protein was added to each tube and incubated for 1 hour on ice. Cells were washed with cold PBS (Gibco) to remove unbound antibody and resuspended in 500 μL cold PBS. Samples were transferred to counting vials, and cell-associated radioactivity was determined by gamma counting (Hidex Automatic Gamma Counter).
- Counts per minute (CPM) from study samples were converted to μCi of In-111 using CPM value using a linear regression created using known amounts of In-111 labeled protein. μCi Bound Values were converted to Moles Bound using the following calculation: (μCi Bound/Specific Activity)/MW mAb or Protein. Each data point is the mean of duplicate samples.
- Click labeled In-111 anti-PSMA mAb and In-111 transferrin bound to C4-2B cells with amounts of cell-associated radioactivity increasing with increasing cell number (
FIG. 3A ). Click labeled In-111 anti-EGFR antibodies Panitumumab and Cetuximab bound to A431 cells with amounts of cell-associated radioactivity increasing with increasing cell number; no specific binding of the click labeled anti-EGFR antibodies was detected with the negative control MOLM-13 cells (FIG. 3B ). - The kinetics of internalization of In-111 click-labeled anti-PSMA mAb in C4-2B cells was determined.
- Cells were seeded at 3×106 cells per 60 mm dish (Corning) and placed in 37° C. humidified CO2 incubator overnight. Seeding media was removed and replaced with 2 mL cold Stain Buffer (BD Biosciences). Dishes were then placed on ice. 0.5 μCi In-111 labeled antibody was added to each dish and incubated for 1 hour on ice. Cells were washed with cold PBS (Gibco) to remove unbound antibody from the cell surface. At various timepoints cells were assayed for surface membrane bound radioactivity and intracellular radioactivity as described below.
- Surface-bound radioactivity was stripped using an acid wash stripping procedure: 1.5 mL Stripping Buffer (50 mM glycine, 150 mM NaCl pH 2.7 with pepsin (Amresco) added to 25 μg/mL) was added to cells, and dishes were incubated on ice for 15 minutes. Stripping Buffer was transferred to counting vials. Cells were washed with cold PBS, and washes were transferred to counting vials. Radioactivity was assayed by gamma counting (Hidex Automatic Gamma Counter). Surface membrane bound radioactivity was determined as the sum of the Stripping Buffer+PBS Washes.
- Intracellular radioactivity was assayed by preparing cell lysates: After surface-bound radioactivity was stripped and cells were washed, 1.5 mL 1 M NaOH (Teknova) was added to cells, and dishes were incubated on ice for 5 minutes. Surface-Stripped Cell Lysates were transferred to counting vials. Dishes were washed with cold PBS, and washes were transferred to counting vials. Radioactivity was assayed by gamma counting (Hidex Automatic Gamma Counter). Intracellular radioactivity was determined as the sum of the Surface-Stripped Cell Lysates+PBS Washes.
- For Time=0 samples, cells were assayed for surface membrane bound radioactivity and intracellular radioactivity immediately after initial antibody binding on ice. For 10-minute, 30-minute, 1-hour and 2-hour samples, 3 mL cell culture media was added to each dish after initial antibody binding and dishes were placed in 37° C. humidified CO2 incubator. At each timepoint, dishes were removed from the incubator and placed on ice. Cell culture media was transferred to counting vials, and cells were washed with cold PBS. PBS washes were collected into counting vials. Cells were assayed for surface membrane bound radioactivity and intracellular radioactivity as described. At each timepoint, an Unstripped Sample was generated by incubating cells with PBS instead of Stripping Buffer prior to Cell Lysis. These samples were used to evaluate stripping efficiency and to compare results with Stripped samples.
- CPM from study samples were converted to μCi In-111 using CPM value from a linear regression created using known amounts of In-111 labeled mAb. Percent Localization of In-111 mAb on cell surface membrane (stripped samples) and intracellular (lysed samples) was determined using the following formula: % Localized=100*(Sample μCi/Average Total μCi), where Total μCi refers to the addition of all collected samples including incubation media, PBS washes, glycine rinses and lysed cells. Each data point is the mean of duplicate samples.
- Surface bound In-111 rapidly disappeared from the cell surface and was redistributed intracellularly. The stripping technique released 80% of the cell surface associated radioactivity at
time 0; by the end of the incubation only 20% was released by stripping and over 60% of the radioactivity was in the cell lysate (FIG. 4 ). - Dose Ranging Study of Anti-PSMA mAb-DOTA-Ac-225:
- Male NSG mice (N=8 per group) were implanted subcutaneously with 106 LNCaP cells, and tumors grew to 100-150 mm3.
- Mice were injected intravenously with a single dose of anti-PSMA mAb-azide-DOTA-225Ac or isotype control, control mAb-azide-DOTA-225Ac at a range of activities (10 nCi, 25 nCi, 70 nCi, 200 nCi). Injected dose per mouse was made up to a total of 10 μg protein with cold antibody. Tumor size and body weight were measured twice-weekly. Animals were euthanized when tumor size exceeded 1,500 mm3, or body weight loss exceeded 20%.
- Anti-PSMA mAb-DOTA-Ac-225 shows tumor growth inhibition after a single dose, particularly at the higher radioactive doses, and superior to isotype control at all doses (
FIG. 5A ). All doses of the control mAb radioconjugate had similar survival curves to the vehicle control (FIG. 5B ; Table 7); the anti-PSMA mAb conjugate showed a clear dose-response with survival increasing with increasing radioactive dose (FIG. 5C ; Table 7). The study was terminated after 209 days, with 3 mice remaining, all from theanti-PSMA mAb 200 nCi group and showing no detectable tumors. -
TABLE 7 Median survival Dose anti-PSMA mAb Isotype control 10 nCi 61 d 46 d 25 nCi 82 d 48 d 70 nCi 92.5 d 50 d 200 nCi 126.5 d 39.5 d Vehicle 46 - The embodiments of the invention are intended to be merely exemplary, and those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures of the invention. All such equivalents are considered to be within the scope of the present invention and are covered by the following claims.
- All references (including patent applications, patents, and publications) cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
Claims (32)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/955,094 US20210017099A1 (en) | 2017-12-18 | 2018-12-17 | Radiolabeling of polypeptides |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762599830P | 2017-12-18 | 2017-12-18 | |
US16/955,094 US20210017099A1 (en) | 2017-12-18 | 2018-12-17 | Radiolabeling of polypeptides |
PCT/US2018/065913 WO2019125982A1 (en) | 2017-12-18 | 2018-12-17 | Radiolabeling of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210017099A1 true US20210017099A1 (en) | 2021-01-21 |
Family
ID=65003549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/955,094 Pending US20210017099A1 (en) | 2017-12-18 | 2018-12-17 | Radiolabeling of polypeptides |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210017099A1 (en) |
EP (1) | EP3727474A1 (en) |
JP (2) | JP2021506842A (en) |
KR (1) | KR20200100094A (en) |
CN (1) | CN111491670A (en) |
AU (1) | AU2018388467A1 (en) |
BR (1) | BR112020012099A2 (en) |
CA (1) | CA3085465A1 (en) |
EA (1) | EA202091420A1 (en) |
IL (1) | IL275242A (en) |
MX (1) | MX2020006395A (en) |
PH (1) | PH12020550690A1 (en) |
SG (1) | SG11202004906QA (en) |
WO (1) | WO2019125982A1 (en) |
ZA (1) | ZA202004424B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022241054A1 (en) * | 2021-05-11 | 2022-11-17 | Northeastern University | Site-specific modification of glycoproteins through transglutaminase-mediated conjugation |
WO2024059908A1 (en) * | 2022-09-21 | 2024-03-28 | The University Of Melbourne | Radiolabelled compounds |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200303A1 (en) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | Psma binding agents and uses thereof |
AR118720A1 (en) * | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | METHODS FOR TREATING PROSTATE CANCER WITH AN ANTI-PSMA / CD3 ANTIBODY |
CR20210556A (en) | 2019-05-10 | 2021-12-17 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof |
US20220259698A1 (en) * | 2019-07-30 | 2022-08-18 | Jfe Engineering Corporation | Method for synthesizing zirconium complex |
BR112022007240A2 (en) | 2019-10-18 | 2022-07-05 | Nihon Mediphysics Co Ltd | METHOD FOR PRODUCING AN ANTIBODY LABELED WITH RADIOACTIVE METAL, ANTIBODY LABELED WITH RADIOACTIVE METAL, CHELATE CONNECTOR, AND, ANTIBODY MODIFIED WITH PEPTIDE |
CN114929717A (en) * | 2020-01-16 | 2022-08-19 | 杰富意工程技术株式会社 | Method for synthesizing zirconium complex |
TW202144418A (en) | 2020-03-13 | 2021-12-01 | 美商健生生物科技公司 | Materials and methods for sialic acid binding ig-like lectin binding |
WO2021236716A2 (en) * | 2020-05-19 | 2021-11-25 | Board Of Regents, The University Of Texas System | Methods, systems and kits for polypeptide processing and analysis |
JPWO2022080481A1 (en) | 2020-10-16 | 2022-04-21 | ||
EP4317152A1 (en) | 2021-03-26 | 2024-02-07 | Nihon Medi-Physics Co., Ltd. | Compound, method for producing and method for storing compound, method for producing targeting agent, and composition |
AU2022250323A1 (en) * | 2021-03-31 | 2023-11-09 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
WO2023190402A1 (en) * | 2022-03-30 | 2023-10-05 | 日本メジフィジックス株式会社 | Method for producing complex |
WO2024030772A1 (en) * | 2022-08-01 | 2024-02-08 | Portland State University | High relaxivity contrast agents and stereoselective preparation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US20080220448A1 (en) * | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
CA2768013C (en) * | 2009-07-15 | 2018-08-21 | Prometheus Laboratories Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
WO2012012612A2 (en) | 2010-07-23 | 2012-01-26 | University Of Delaware | Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes |
WO2012075361A2 (en) * | 2010-12-02 | 2012-06-07 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
WO2013003555A1 (en) * | 2011-06-28 | 2013-01-03 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
EP2912459A2 (en) * | 2012-10-25 | 2015-09-02 | Life Technologies Corporation | Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins |
EP2935611B1 (en) * | 2013-10-14 | 2021-07-07 | SynAffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
WO2015073746A2 (en) | 2013-11-13 | 2015-05-21 | Whitehead Institute For Biomedical Research | 18f labeling of proteins using sortases |
EP3142710A4 (en) * | 2014-05-16 | 2018-04-25 | Memorial Sloan Kettering Cancer Center | One-step labeling of antibodies to high specific activity with actinium-225 |
GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
US10758895B2 (en) * | 2014-09-30 | 2020-09-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Cu(I)-catalyzed azide-alkyne cycloadditions (CuAAC) ligands and methods for carrying out Cu(I)-catalyzed azide-alkyne cycloaddition reactions |
GB201504064D0 (en) * | 2015-03-10 | 2015-04-22 | Accretion Biotechnology Ltd | Method and kits for preparing radionuclide complexes |
-
2018
- 2018-12-17 AU AU2018388467A patent/AU2018388467A1/en active Pending
- 2018-12-17 KR KR1020207019135A patent/KR20200100094A/en not_active Application Discontinuation
- 2018-12-17 SG SG11202004906QA patent/SG11202004906QA/en unknown
- 2018-12-17 JP JP2020533250A patent/JP2021506842A/en active Pending
- 2018-12-17 EA EA202091420A patent/EA202091420A1/en unknown
- 2018-12-17 EP EP18830649.2A patent/EP3727474A1/en active Pending
- 2018-12-17 BR BR112020012099-5A patent/BR112020012099A2/en unknown
- 2018-12-17 CN CN201880081895.2A patent/CN111491670A/en active Pending
- 2018-12-17 CA CA3085465A patent/CA3085465A1/en active Pending
- 2018-12-17 WO PCT/US2018/065913 patent/WO2019125982A1/en unknown
- 2018-12-17 MX MX2020006395A patent/MX2020006395A/en unknown
- 2018-12-17 US US16/955,094 patent/US20210017099A1/en active Pending
-
2020
- 2020-05-22 PH PH12020550690A patent/PH12020550690A1/en unknown
- 2020-06-09 IL IL275242A patent/IL275242A/en unknown
- 2020-07-17 ZA ZA2020/04424A patent/ZA202004424B/en unknown
-
2023
- 2023-03-22 JP JP2023045468A patent/JP2023078366A/en active Pending
Non-Patent Citations (12)
Title |
---|
Almeida et al. (Angew Chem. Int. Ed. Engl. 2012 Mar 5; 51 (10): 2443-7) * |
Chen et al. (ACS Med. Chem. Lett. 2012 Sep 19; 3 (12): 1019-23) * |
Chomet et al. (Bioconjug. Chem. 2021 Jul 21; 32 (7): 1315-1330) * |
Jeon et al. (Bioorg. Med. Chem. 2015 Jul 1; 23 (13): 3303-8) * |
Jin et al. (Signal Transduct. Target Ther. 2022 Feb 7; 7 (1): 39; pp. 1-28) * |
Khatwani et al. (Bioorg. Med. Chem. 2012 Jul 15; 20 (14): 4532-9) * |
Morais et al. (Drug Discov. Today Technol. 2018 Dec; 30: 91-104) * |
Nováková et al. (Prostate. 2017 May; 77 (7): 749-64; author manuscript; pp. 1-28) * |
Schmittgen et al. (Int. J. Cancer. 2003 Nov 1; 107 (2): 323-9) * |
Sharkey et al. (J. Nucl. Med. 2005 Jan; 46 (Suppl. 1): 115S-27S) * |
Wei et al. (Chem. Rev. 2020 Apr 22; 120 (8): 3787-3851) * |
Zeglis et al. (Bioconjug. Chem. 2013 Jun 19; 24 (6): 1057-67) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022241054A1 (en) * | 2021-05-11 | 2022-11-17 | Northeastern University | Site-specific modification of glycoproteins through transglutaminase-mediated conjugation |
WO2024059908A1 (en) * | 2022-09-21 | 2024-03-28 | The University Of Melbourne | Radiolabelled compounds |
Also Published As
Publication number | Publication date |
---|---|
KR20200100094A (en) | 2020-08-25 |
JP2023078366A (en) | 2023-06-06 |
IL275242A (en) | 2020-07-30 |
CA3085465A1 (en) | 2019-06-27 |
WO2019125982A1 (en) | 2019-06-27 |
SG11202004906QA (en) | 2020-07-29 |
BR112020012099A2 (en) | 2020-11-17 |
AU2018388467A1 (en) | 2020-06-11 |
ZA202004424B (en) | 2022-06-29 |
EP3727474A1 (en) | 2020-10-28 |
EA202091420A1 (en) | 2020-09-10 |
PH12020550690A1 (en) | 2021-04-12 |
MX2020006395A (en) | 2020-12-03 |
JP2021506842A (en) | 2021-02-22 |
CN111491670A (en) | 2020-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210017099A1 (en) | Radiolabeling of polypeptides | |
US11576986B2 (en) | Macrocyclic chelators and methods of use thereof | |
EP3089758B1 (en) | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof | |
Wu et al. | Synthesis of site-specific radiolabeled antibodies for radioimmunotherapy via genetic code expansion | |
Schubert et al. | Novel tumor pretargeting system based on complementary l-configured oligonucleotides | |
AU2022213825A1 (en) | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
Farleigh et al. | New Bifunctional Chelators Incorporating Dibromomaleimide Groups for Radiolabeling of Antibodies with Positron Emission Tomography Imaging Radioisotopes | |
US20220143231A1 (en) | Macrocyclic compounds and methods of use thereof | |
KR20240014479A (en) | Compositions and methods for treating prostate cancer | |
Bejot et al. | Aminooxy‐functionalized DOTA for radiolabeling of oxidized antibodies: evaluation of site‐specific 111In‐labeled trastuzumab | |
EA045797B1 (en) | RADIOACTIVE LABELING OF POLYPEPTIDES | |
EP4327831A1 (en) | Radioactive complex of anti-cd20 antibody, and radiopharmaceutical | |
US20240207464A1 (en) | Radioactive complex of anti-cd20 antibody, and radiopharmaceutical | |
EP4230637A1 (en) | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical | |
US20240207463A1 (en) | Radioactive complex of anti-egfr antibody, and radiopharmaceutical | |
WO2023084397A1 (en) | Macrocyclic compounds and diagnostic uses thereof | |
WO2022246183A1 (en) | Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use | |
WO2023144723A1 (en) | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
KR20230163487A (en) | Radiocomplexes and radiopharmaceuticals of anti-EGFR antibodies | |
AU2021361746A9 (en) | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical | |
TW202325343A (en) | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product | |
CN116806159A (en) | Immunoconjugates comprising kallikrein-related peptidase 2 antigen binding domains and uses thereof | |
CN117769440A (en) | Radioactive complexes and radiopharmaceuticals of anti-CD 20 antibodies | |
CN117377690A (en) | Radioactive complexes and radiopharmaceuticals of anti-EGFR antibodies | |
Dennler | Microbial Transglutaminase as a Versatile Tool for Site-Specific Protein Modification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JANSSEN BIOTECH, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUDKIN, VADIM;GOLDBERG, SHALOM;ERHARDT, JOSEPH;AND OTHERS;SIGNING DATES FROM 20200526 TO 20200625;REEL/FRAME:053261/0001 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: EX PARTE QUAYLE ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO EX PARTE QUAYLE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |